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Abstract 
Cartilage injury, which can lead to arthritis, currently lacks any effective 
treatment, and so the design of chondroinductive biomaterials holds a compelling 
appeal for the field of regenerative medicine. Although chondroinductive signaling 
pathways are conventionally activated by cellular communication with growth 
factors and extracellular matrix (ECM) components, these natural molecules have 
translational limitations such as immunogenicity, lack of reproducibility, and high 
cost. As a result, designing acellular chondroinductive biomaterials with no animal-
derived elements presents a clearly superior approach for commercial 
applications. 
 
Growth factor and ECM molecules often contain cell-binding sequences 
that could potentially be reproduced in synthetic peptides, and this idea provides 
the rationale for the current dissertation: evaluation of the chondroinductivity of 
synthetic peptides to mimic the effects of growth factors and ECM components in 
cartilage repair. I identified the peptide candidate, SPPEPS, as a matching 
sequence of two chondroinductive molecules, aggrecan proteoglycan and 
transforming growth factor-3 (TGF-3).  The N-terminal subunit of TGF-3 is known 
as the latency-associated protein (LAP) and the SPPEPS peptide sequence 
belongs to the LAP region of TGF-3 which is known to be a ligand for a number 
of integrins and integrins play a critical role in cartilage regeneration. First, the 
properties of SPPEPS and Link N peptides were evaluated in rat bone marrow 
xi 
mesenchymal stem cells (rBMSCs), demonstrating their potential as 
chondroinductive sequence. Next, I compared the properties of the SPPEPS 
peptide in isolation and when incorporated with RGD into pentenoate-
functionalized hyaluronic acid (PHA) hydrogels, thereby demonstrating the 
chondroinductive potential of PHA hydrogels. Finally, chondroinductivity was 
evaluated for SPPEPS or RGD peptides conjugated into PHA hydrogel networks 
and demonstrated the potential for hydrogels with crosslinked SPPEPS peptides 
to regenerate tissue with prevalent collagen type II production, which is a faithful 
reproduction of native hyaline cartilage. Future studies will focus on evaluating the 
chondroinductivity of PHA hydrogel with different concentrations of SPPEPS 
peptide, in addition to designing of bifunctional materials with desirable mechanical 
integrity. 
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Chapter 1: Introduction 
Cartilage injury lacks effective treatment and it may eventually lead to 
further degeneration of the tissue, including conditions such as arthritis. This 
unfortunate situation motivates the work described in this dissertation: the design 
of a chondroinductive (i.e., cartilage regenerating) biomaterial to assist in the repair 
of cartilage defects. Although natural molecules such as growth factors and 
extracellular matrix components could be incorporated into biomaterials to emulate 
natural cellular environments, thereby stimulating cartilage regeneration, such 
molecules present significant barriers to commercial adoption: they are expensive, 
lack reproducibility, and are prone to risks associated with immunogenicity. The 
main focus of this dissertation was therefore to investigate whether small synthetic 
peptides can mimic the effects of cell adhesion motifs from natural molecules, and 
if such peptides can affect cellular differentiation, specifically chondrogenic 
differentiation. Chondroinductive peptide sequences, if indeed they exist, might 
therefore be incorporated into chondroinductive biomaterials for the treatment of 
cartilage injury.  
 
At the beginning of this thesis, we did not have any peptide candidates. In 
an exploratory and high-risk/high-reward journey, my thesis tells the story of the 
thought process behind parallel approaches to identify potential candidates, their 
evaluation, and the ultimate selection of a leading candidate that is currently the 
basis of a provisional U.S. patent application.  
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 The story begins by looking outside of the field of regenerative medicine. 
Receptor-binding peptides, and methods to identify them, are a major focus in 
cancer research. By taking our cue from cancer therapy research, we may 
potentially create 100% synthetic biomaterials with the following steps: 1) Identify 
the receptors involved in cartilage regeneration; 2) Design peptides that bind the 
receptors and activate desired signaling pathways; 3) Incorporate these peptides 
into suitable biomaterials. If successful, this approach could revolutionize the 
treatment of injured cartilage. With these design steps in mind, the Specific Aims 
for this thesis were: (1) to evaluate the effects of synthetic peptides on 
chondrogenic differentiation of rat bone marrow-derived mesenchymal stem cells 
(rBMSCs), (2) to evaluate the chondroinductivity of synthetic peptides conjugated 
to pentenoate-functionalized hyaluronic acid (PHA) hydrogels in vitro. (3) to 
evaluate the potential of the synthetic peptides conjugated to PHA in regenerating 
hyaline-like cartilage tissue in vivo.  
 
In my Aim 1, various candidate peptides were either dissolved in the cell 
culture medium or used as coatings for cell culture plates. The superior peptide 
was chosen for further studies in Aim 2, where chondroinductivity was evaluated 
when the peptide was crosslinked to pentenoate-functionalized hyaluronic acid 
(PHA) hydrogel networks in vitro. Cognizant of the differences between 
chondrogenic effects in a laboratory experiment and in a physiological context, my 
Aim 3 was to evaluate the efficacy of the peptide in regenerating a cartilage-like 
tissue when conjugated to PHA hydrogels in vivo. 
3 
Chapter 2 is a review of the literature that introduces the idea of designing 
biomaterials tailored to desired cell-matrix interactions by incorporation of 
peptides. Moreover, this review introduces the methods of identifying the peptides 
and the important role of cell adhesion peptides and cell adhesion integrins in 
cartilage. This review chapter provides the foundation for my vision for the study 
design in the chapters that follow. The review addresses the limitations of the 
approaches that use natural molecules as components for biomaterials in 
regenerative medicine and provides suggestions for new strategies for identifying 
chondroinductive peptide sequences focused on integrin-peptide interactions 
which may lead to chondrogenic differentiation of stem cells.  
 
Chapter 3 addresses Aims 1 and 2, i.e., the in vitro evaluation of two 
peptides (i.e., Link N and SPPEPS) in terms of chondroinductivity. I identified (Ser-
Pro-Pro-Glu-Pro-Ser, SPPEPS) as a matching sequence of two chondroinductive 
molecules, the core protein of the proteoglycan aggrecan, and transforming growth 
factor-3 (TGF-3). The chondroinductivity of the peptide was evaluated for the first 
time and the encouraging results led to proteomics analysis on the rBMSCs 
exposed SPPEPS to further evaluate the protein profile and signaling pathways 
upregulated by the peptide. In addition, SPPEPS was conjugated to PHA 
hydrogels and the chondroinductivity was evaluated by qPCR for rBMSCs cultured 
on top of the hydrogels. PHA hydrogel was chosen as a carrier system due to its 
fast crosslinking time (1-2 minutes) which is attractive for surgical applications. In 
4 
Chapter 3, the SPPEPS peptide supported chondrogenic differentiation in vitro and 
therefore was chosen for further in vivo evaluation in Chapter 4.  
 
Chapter 4 addresses Aim 3, i.e., the in vivo potential of a PHA hydrogel 
when it is conjugated to either SPPEPS or RGD in regenerating a hyaline-like 
tissue, using a rabbit femoral condyle model. The regenerated tissue was 
assessed based on the gross morphology, Hematoxylin & Eosin staining, Alcian 
Blue staining and collagen II immunohistochemistry.  
 
Chapter 5 concludes this thesis with a summary of key results and 
interpretations. I provide not only recommendations for further analysis, but also 
possible future research directions in the field to design the next generation of 
materials for articular cartilage regeneration.  
 
In this thesis, the study designs and all the experiments were done by 
myself except the proteomics experiment in the first aim, which was conducted by 
the Laboratory for Molecular Biology and Cytometry Research at the University of 
Oklahoma Health Sciences Center. However, the identification of analysis 
methods and the raw data evaluation was done by myself. For the third aim, the 
study protocols for Institutional Animal Care and Use Committee (IACUC) 
approval, the study design, surgical room preparation, monitoring the animal’s 
wellbeing, harvesting and preparing the tissue for histology analysis was done by 
myself. The sectioning, Alcian Blue and H&E staining of the tissues were 
5 
performed by the Stephenson Cancer Tissue Pathology Core at the University of 
Oklahoma Health Sciences Center and the Immunohistochemistry staining was 
done by myself. 
Overall the work presented in the current dissertation introduced a novel 
approach in designing chondroinductive biomaterials and provided the first step in 
the design of acellular synthetic chondroinductive biomaterials with the goal of 
developing cost-effective and highly translatable treatments.  
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Chapter 2: Chondroinductive Peptides: Drawing Inspirations 
from Cell-Matrix Interactions1 
 
Abstract 
 In the field of regenerative medicine, creating a biomaterial device with the 
potential to alone affect cellular fate is a desirable translational strategy. Native 
tissues and growth factors are attractive candidates to provide desired signals in 
a biomaterial environment; however, these molecules can have translational 
challenges such as high cost, complicated regulatory pathways, and/or limitations 
with reproducibility. In regenerative medicine, there is a burgeoning community of 
investigators who seek to overcome these challenges by introducing synthetic 
peptides to mimic the desirable signals provided by growth factors and tissue 
matrices. Since in cartilage tissue, cell-adhesion signaling mediates cell migration, 
growth, and differentiation, synthetic peptides that mimic a desired cell-adhesion 
sequence may help to control cellular fate. This chapter emphasizes the value of 
the signaling ability of peptides, specifically in the cartilage regeneration field. The 
primary challenge in cartilage regeneration is to regenerate true hyaline cartilage 
instead of a fibrous tissue. The vision is to create materials that take advantage of 
the signaling abilities of peptides and that themselves induce chondrogenesis 
without the need for tissue-derived matrix or growth factors, which can potentially 
revolutionize arthritis prevention and treatment.  
 
   
1Published as: Mahzoon S, Detamore MS. Chondroinductive Peptides: Drawing Inspirations from 
Cell-Matrix Interactions. Tissue Engineering Part B, 2018. 
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Introduction 
It is estimated that 78 million adults aged 18 years or older in the U.S. (26% 
of the population) will be diagnosed with arthritis by the year 2040 (Centers for 
Disease Control and Prevention; Nov 20, 2016). Despite arthritis being one of the 
leading causes of disability, it does not yet have an effective treatment and may 
develop following a cartilage injury. There are surgical treatments that aim to repair 
cartilage tissue such as autologous chondrocyte implantation (ACI), microfracture, 
osteochondral transplantation (mosaicplasty), and allograft implants. Although 
these treatments may provide clinical improvement, they are generally not 
successful in producing a tissue with the same long-term mechanical and chemical 
properties of native articular cartilage. The deficiency of the treatments to produce 
an effective cartilage tissue has created an impetus for the regenerative medicine 
community to establish strategies that lead to restoration of a fully functional 
hyaline cartilage.1 
 
 To design a bioactive material, one approach includes the incorporation of 
natural components such as extracellular matrix (ECM) molecules or growth 
factors in a scaffold structure. Although natural components might be able to mimic 
the native environment for the cells and enhance cartilage formation, 
disadvantages such as high cost, limitations of reproducibility, and the risks 
involved with immunogenicity can be significant limitations for commercialization. 
Therefore, a synthetic product with the potential of inducing cartilage regeneration 
without the need for human- or animal-derived elements (if indeed such a material 
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exists) would present a more attractive translational option. Synthetic biomaterials 
may be utilized for acellular applications where the cartilage regeneration does not 
rely on cell-based therapies,2-4 although there are applications where a cell-based 
strategy may be required, for example in regeneration of the entire joint surface,5, 
6 and a chondroinductive biomaterial would be advantageous in either case. In 
cartilage regeneration, the goal of designing an all-synthetic biomaterial is to create 
scaffolds with desired mechanical integrity and the ability to lead endogenous 
mesenchymal stem cells (MSCs) toward chondrogenic differentiation and prevent 
chondrocyte dedifferentiation. The properties of synthetic biomaterials may be 
tailored by changing the polymer composition to achieve desirable failure 
properties (e.g., maximum stress, strain, and toughness);7 however, the remaining 
challenge is incorporating all-synthetic cellular signals to replace ECM molecules 
and growth factors to lead endogenous stem cells to chondrogenic differentiation 
and prevent chondrocyte dedifferentiation. 
 
Peptides have the potential to mimic ligands and act through desired cellular 
signaling pathways. Identifying the bioactive peptides that are chondroinductive 
and then incorporating them in a biomaterial may lead to 100% synthetic 
chondroinductive biomaterials, which may potentially revolutionize the field of 
cartilage injury treatment.  
 
Perhaps the regenerative medicine community may take a cue from the 
cancer field, as identifying receptor-binding peptides is a crucial research focus for 
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oncological therapy. Delivery of a therapeutic with receptor-binding peptides 
decreases the side effects of the therapeutic compared to chemotherapeutic 
methods, in which the drugs are given to the patients at concentrations 
approaching maximum body tolerance with low efficiency.1 The regenerative 
medicine community may likewise design synthetic bioactive materials by 
incorporating receptor-binding peptides in the material structure to take advantage 
of their signaling abilities.    
 
In regenerative medicine, there are a select group of pioneering studies that 
have employed peptides as direct signals.8-13 In addition, there are review papers 
that have eloquently covered receptor-binding peptides;1, 14 however, they have 
not focused on peptide applications for regenerative medicine nor the approaches 
of identifying peptides that may help with cellular differentiation. 
 
This chapter provides an overview of cartilage regeneration studies that 
have taken advantage of bioactive peptides for their potential of affecting cellular 
fate. Furthermore, we emphasize cell-matrix adhesion, adhesion receptors, and 
methods of identifying adhesion receptor-binding peptides as a potential strategy 
to affect cellular differentiation and induce chondrogenic differentiation.  
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Potential Chondroinductive Peptides in Cartilage Regeneration  
The most common methods of incorporating receptor-binding peptides in 
biomaterials are using peptides as a coating for scaffold surfaces and conjugating 
the peptides to polymers in scaffolds. Incorporating small peptides in biomaterials 
for regenerative medicine is attractive because short peptide sequences can be 
synthesized reproducibly in large quantities, their small size reduces the chance 
of non-specific binding, and they have the potential to affect cellular fate. Arginine-
glycine-aspartate (RGD) peptides are attractive because of their cell-adhesion 
properties and as a result, RGD is the most commonly used receptor-binding 
peptide across a variety of applications. However, there are only a few peptides 
that have been employed in the cartilage regeneration field for their capacity to 
potentially induce chondrogenic differentiation. Given below is a concise overview 
of each of these studies. 
 
Link N Peptide 
Link protein is a glycoprotein that stabilizes the non-covalent interaction of 
hyaluronate and aggrecan molecule G1 domain15 and the Link N sequence 
(DHLSDNYTLDHDRAIH) is the amino-terminal peptide of the link protein. In 2013, 
Wang et al.16 indicated that the Link N sequence acts through the BMP type II 
receptor. There are several studies that investigated the potential of Link N 
sequence in improving cartilage tissue regeneration both in vitro and in vivo.17 
In 2003, Mwale and co-workers showed that adding 100 ng/mL Link N to the 
culture medium of both nucleus pulposus (NP) and annulus fibrous (AF) cells 
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isolated from bovine intervertebral discs (IVDs) every two days increased the 
glycosaminoglycan (GAG) and collagen types II and IX accumulation after 20 days. 
Type II collagen and type IX collagen contents were measured by ELISAs and 
GAG content was measured by the DMMB assay.15 In another study, Gawri et al. 
reported that injecting 50 μL Link N with concentration 20 mg/mL into healthy intact 
IVDs isolated from 13 adult human donors promoted aggrecan synthesis 
compared to the control group (50 μL 35SO4). Aggrecan synthesis was assayed by 
estimating 35SO4 incorporation in intact IVDs after 48 hours.18 Injecting Link N with 
concentration 10 mg/mL into 5 mm deep annular punctures in the center of NP of 
19 New Zealand White rabbit IVDs significantly increased the aggrecan expression 
for both NP and AF after two weeks.19 
 
GFOGER Peptide 
The GFOGERGVEG-POGPA peptide sequence was identified for its ability 
to bind the α2β1 integrin. The peptide was recognized by comparing the binding 
abilities of overlapping peptides from collagen I, α1(I)CB3 domain to the α2β1 
receptor.20, 21 In 2000, Knight and co-workers22 reported that removal of the GER 
sequence from GFOGERGVEG-POGPA sequence stopped the peptide from 
binding to α2β1; however, the removal of its C-terminal had no evident effect on the 
level of the peptide adhesion to α2β1 integrin. This study further indicated the ability 
of the GFOGER peptide to bind to the α2β1 receptor by demonstrating that the 
adhesion of collagen I to the receptor was inhibited by GFOGER.  
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In 2010, Liu et al.23 incorporated GFOGER into poly(ethylene glycol) (PEG) 
hydrogels through Michael addition chemistry. Human MSCs were encapsulated 
in PEG hydrogels with and without GFOGER. After 9 days, the relative gene 
expressions of collagen types II and X and aggrecan were higher in the groups 
with the GFOGER peptide.  
 
B2A2 Peptide   
The B2A2 peptide consists of a receptor targeting domain, a hydrophobic 
spacer domain, and a heparin-binding domain. The peptide was designed in 1999 
to bind to heparin and endothelial cell proteoglycans.24 In 2005, the peptide was 
recognized for its ability to bind to the BMP-2 receptor.25, 26 Since BMP receptors 
are involved in chondrocyte formation, in 2012 Lin et al.27 hypothesized that the 
B2A2-K-NS peptide could play a role in cartilage repair. To test their hypothesis, 
they added 10 μg/mL of the peptide to murine embryonic stem cell medium every 
three days. After seven days, gene expression of SOX9 and collagen type Il 
increased compared to the non-treated group (i.e., medium without the peptide). 
To identify the effects of the peptide on cartilage regeneration in vivo, osteoarthritis 
was chemically induced in the knees of six adult rats by injecting monoiodoacetate 
(MIA) into the synovial space. At days 7 and 14, 500 ng of the peptide was injected 
to the knees. After 21 days, the histological analyses indicated that the B2A2 
treatment enhanced cartilage repair compared to untreated knees, which received 
saline instead of the peptide.  
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KIPKASSVPTELSAISTLYL Peptide  
The KIPKASSVPTELSAISTLYL sequence, which is known as the BMP2 
peptide, corresponds to residues 73–92 of the knuckle epitope of bone 
morphogenetic protein-2 (BMP-2). This peptide was identified in 2003 as a 
potential candidate to improve bone formation through raising alkaline 
phosphatase activity compared to the other overlapping peptides of knuckle 
epitope of BMP-2.28-30 In 2012, the ability of the peptide to direct chondrogenesis 
was investigated when it was added to the human MSC medium (100 ng/mL) three 
times per week. The gene expressions for aggrecan (after three days) and SOX9 
and collagen type II (both after one week) were significantly higher than the 
negative control (no growth factor in the medium).31 
 
N-Cadherin Mimetic Peptide 
Cell-cell adhesion plays an important role in initiating chondrogenesis. In 
several studies, peptides that mimic cell-cell interactions have been used as a 
strategy for designing chondroinductive biomaterials.32, 33 In 2012 it was shown 
that functionalization of hyaluronic acid (HA) hydrogels with N-cadherin mimetic 
peptides increased GAG and total collagen content of encapsulated MSCs after 
28 days, when compared to MSCs encapsulated in HA hydrogels functionalized 
with scrambled N-cadherin mimetic peptides.34, 35  
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Self-Assembled Peptides 
Several studies investigated the potential of self-assembled peptide 
hydrogels in modulating chondrogenesis. Self-assembled peptide hydrogels have 
been the focus of regenerative medicine applications due to their favorable 
physical properties; these hydrogels are made from natural building blocks and 
they may provide safe degradation products. Their physical properties such as 
pore size, fiber thickness, and mechanical performance can be tuned, and may 
improve a material’s biological properties if biologically relevant peptides are 
used.36-44 In the cartilage regeneration field, it was shown that encapsulating MSCs 
for 21 days in self-assembled peptides resulted in higher glycosaminoglycan 
content and more spatially uniform proteoglycan and collagen type II deposition 
when compared to MSCs encapsulated in agarose hydrogels.45, 46 
 
Cell-Matrix Adhesion and Chondrogenic Differentiation 
It is widely known that adhesion molecules are crucial in mediating multiple 
cellular signaling pathways,47, 48 and have a high impact on critical cellular 
processes such as gene expression, cell cycle, and programmed cell death.50  
 
Key components of cell-adhesion can be divided into three main groups: 
adhesion receptors, ECM proteins, and cytoplasmic plaque membrane proteins. 
The adhesion receptors have a critical role in mediating cell-cell and cell-ECM 
signaling, and they are typically classified using four groups: integrins, cadherins, 
immunoglobulins, and selectins. These receptors have been the subject of 
15 
significant interest, as reflected by the thousands of publications that describe 
them in detail.49, 50 In this review, we provide only a brief overview given that more 
extensive descriptions are available elsewhere.  
 
Adhesion Receptors 
Integrins are known as cell receptors for ECM proteins and mediate cell-
ECM adhesion.  The structure of each integrin consists of an α and a β subunit, 
with both subunits composed of three main domains: an extracellular domain, a 
cytoplasmic region, and a single membrane-spanning domain. There are at least 
16 α and eight β subunits known for integrins, and the specific subunit pairing 
determines explicit ligand-integrin binding properties.49, 51-53 Cadherins mediate 
cell-cell adherence junctions and communicate with a group of linking proteins 
called catenins, which are crucial for cadherin function. Cadherins have different 
types of N-, P-, R-, B-, and E-cadherins, all with essential roles in both tissue 
formation and signaling cascade regulation.54-58 Immunoglobulin cell-adhesion 
molecules (Ig-CAMs) are a member of the immunoglobulin superfamily and studies 
show that some are critically engaged in T and B cell activation.59, 60 Selectins are 
smaller families of adhesion receptors that mediate rolling interactions of 
leukocytes on vascular endothelial cells, a therefore play a critical role in controlling 
inflammatory diseases.61-64 
 
 
 
16 
Adhesion Receptors and Cartilage Regeneration 
Cartilage has an ECM-rich environment with a limited number of 
chondrocytes for which the value of ECM as a survival factor has been 
demonstrated.65, 66 Integrins therefore play a critical role in cartilage regeneration 
because integrins mediate cell-ECM signaling pathways. To design 
chondroinductive biomaterials, it is valuable to identify the integrins expressed by 
chondrocytes and the changes of integrin expression during chondrogenic 
differentiation. Incorporating integrin-specific sequences in biomaterials may help 
to better control the cellular differentiation through activating desired adhesion 
signaling pathways. Here we cover the studies focused on identifying chondrocyte-
specific integrins and the studies that aimed to monitor the integrin expression 
modifications during chondrogenic differentiation of stem cells. 
 
Integrin Expression of Chondrocytes 
In 1994, Woods et al.67 investigated the integrins expressed by 
chondrocytes of human healthy knee cartilage. Cartilage tissue was harvested with 
biopsies from adult donors and the chondrocytes were isolated from the tissue. 
The integrin expression of the cells was analyzed by immunohistochemistry using 
monoclonal antibodies against different integrins, which indicated that normal 
human articular chondrocytes display a substantial quantity of α1β1, α5β1 and αvβ5 
integrins as well as limited quantities of α3β1 and αvβ3 integrins. The expressions 
of α1β1, α3β1, and α5β1 were highlighted in 1995 by Loeser and co-workers68 by 
immunostaining chondrocytes harvested from bovine articular cartilage. 
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 In 1998, Camper et al.69 described α10β1 expression by human 
chondrocytes via immunostaining of chondrocytes in tissue sections of human 
cartilage tissue. In 1995, it was shown that the integrin expression of fetal 
chondrocytes is different from that of adult chondrocytes;70 the immunostaining of 
fetal healthy knee sections demonstrated that fetal chondrocytes expressed α6 and 
α2, which are not expressed by adult chondrocytes. In addition, the fetal 
chondrocytes did not express β3 and α3, which were expressed by adult 
chondrocytes in previous studies.  
 
Integrin Expression during Chondrogenic Differentiation 
The variation of integrin expression during chondrogenic differentiation was 
investigated for the first time in 2005 by Goessler et al.71 In this study, the integrin 
expression of human bone marrow MSCs was analyzed with microarray 
hybridization. During the 21 days of chondrogenic differentiation, the expression 
of integrin α5β1 was downregulated while the expression of other integrins 
remained constant. In 2006, the important role of the α5 integrin subunit was further 
emphasized by Connelly and co-workers72 when anti-α5 antibody was added to the 
medium of bone marrow MSCs harvested from the tibiae and femora of an 
immature calf, producing a reduction in GAG accumulation after 6 days relative to 
the untreated control group. In 2007, Goessler et al.73 studied the integrin 
expression of both bone marrow- and adipose-derived human MSCs before and 
after 20 days of chondrogenic differentiation. Microarrays and 
immunohistochemistry indicated that the integrin α5β1 was expressed by 
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undifferentiated MSCs, and its expression rose during chondrogenic differentiation 
of both types of MSCs. A 2013 study indicated the importance of the integrin β8 
subunit during chondrogenic differentiation: β8 expression was upregulated after 
21 days of chondrogenic differentiation of human MCSs when measured by 
quantitative PCR. The knockdown of the β8 receptor via an shRNA lentiviral 
construct resulted in no collagen type II expression, which further supported the 
importance of the β8 receptor in chondrogenic differentiation.74 
 
In summary, the important role of adhesion molecules in regulating cellular 
signaling is widely recognized. The roles of integrins in cartilage tissue and 
chondrocyte signaling are of special importance given the ECM-rich nature of the 
tissue, and the role of integrins in mediating cell-ECM signaling, as cartilage has 
an ECM-rich environment with low cell density. The integrins that affect cartilage 
regeneration are typically categorized into two main groups; the integrins 
expressed by differentiated chondrocytes, and the integrins expressed during 
chondrogenic differentiation.  
 
For the biomaterials that target chondrocytes, utilizing ligands specific to 
integrins of chondrocytes may possibly prevent chondrocyte dedifferentiation and 
contribute in mediating the integrity of cartilage tissue. For the biomaterials that 
target MSCs for chondroinductivity, identifying and incorporating ligands specific 
to the integrins that change expression during chondrogenic differentiation may 
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further improve cartilage tissue development. This approach can therefore 
produce biomaterials with the capability to activate cartilage regeneration. 
 
The current studies in the field of cartilage biology may reveal valuable 
information about the chondrogenic role of integrins, but more extensive studies 
are required to elucidate the contributions of a wider range of integrins and to 
identify the specific role of each integrin during chondrogenic differentiation. 
 
Adhesion Receptor-Binding Peptides  
In 1984, Pierschbacher and Ruoslahti75 indicated that the cell-binding 
potential of fibronectin can be duplicated with the cell attachment domain of 
fibronectin, a peptide sequence with three amino acids (Arg-Gly-Asp, i.e., RGD). 
RGD was subsequently recognized for the ability to bind to 12 integrins.76-80 The 
fact that RGD is the cell attachment site to many other adhesion proteins has given 
this peptide a distinguished position in cell adhesion biology, and numerous 
regenerative medicine and pharmaceutical applications are taking advantage of 
this sequence to design cell adhesion materials.81 The RGD example underscores 
the notion that the binding site of a receptor can indeed be recapitulated by a 
relatively short peptide sequence, which can be used instead of growth factors, 
antibodies, and ECM proteins.82-85 Replacing entire adhesion molecules with a 
short adhesion peptides is attractive because such peptides are easy to synthesize 
in large quantities. Moreover, their small size reduces the chance of any 
nonspecific binding, and they can be designed to obtain a desired cell response. 
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It is important to keep in mind that several distinct proteins can bind to an individual 
receptor.86 For instance, the αvβ3 integrin has been reported to bind to collagen VI, 
laminin, fibronectin, vitronectin, thrombospondin, von Willebrand factor, and 
fibrinogen.87  
 
In addition, a peptide that binds to a desired integrin may be unable to target 
a specific pathway and even inhibit the binding of the other suitable sequences. In 
2006, Connelly et al.72 demonstrated the inhibition of chondrogenesis in RGD-
modified alginate gels. In that study, bovine bone marrow-derived MSCs were 
encapsulated in either RGD- or RGE-modified alginate gels. After 7 days, the 
chondrogenic medium significantly stimulated chondrocytic gene expression (i.e., 
collagen II, aggrecan, and SOX9) in the RGE-modified gels but not in the RGD-
modified gels. The results indicated that RGD interactions significantly inhibit the 
chondrogenic response in terms of gene expression for this particular system. 
 
In cancer therapy, the limitations of current chemotherapeutics make 
identification of adhesion receptor-binding peptides an attractive research topic. In 
chemotherapeutic procedures, the drugs are typically not of maximal efficiency and 
are given to the patients at the highest level of body tolerance. Identifying peptides 
that bind to adhesion receptors of cells, and incorporating them in cancer therapy 
drugs, may reduce side effects as the therapeutic would only target the tumor cells. 
Table 2.1 shows a selected group of adhesion receptor-binding peptides that have 
been discovered for cancer therapy applications.1 
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In summary, the success of the cancer therapy field in identifying peptides 
that bind to specific adhesion receptors indicates opportunities for the regenerative 
medicine community to discover peptides that induce or facilitate 
chondroinductivity by targeting integrins. In addition, the extensive research 
surrounding the RGD sequence indicates the potential of peptides to affect cellular 
fate. Although adhesion receptor-binding peptides have the potential to change 
cellular fate, it is important to keep in mind that the ability of a peptide to bind to 
the target integrin may not always lead to activating the desired signaling pathways 
and may even inhibit the preferred cellular activities. However, an adhesion 
peptide sequence may hold tremendous value for retaining endogenous cells in 
the construct in vivo, and may play a crucial role in a combined strategy with a 
differentiation peptide.  
 
Methods of Identifying Adhesion Receptor-Binding Peptides 
If the regenerative medicine community is to pursue the recognition of novel 
peptide sequences to create desirable cell responses, then eventually the methods 
of identifying them must be understood. Investigators have applied many different 
methods for discovering adhesion receptor-binding peptides, from synthesizing 
overlapping or random sequences of an adhesion protein to using complex peptide 
libraries. 
 
Peptide libraries provide the opportunity to screen the binding ability of a 
given protein in a high throughput manner. Peptide libraries are categorized based 
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on their method of display and can be categorized into two main groups: biological, 
and nonbiological. Biological libraries use DNA, or genotype, to encode peptide 
sequences,1 whereas nonbiological libraries use peptides synthesized in vitro. To 
screen the binding ability of a desired protein or cell line, it is incubated along with 
the peptide library, and unbound peptides are subsequently washed away. The 
remaining peptides are then screened according to their design method. Biological 
libraries include bacterial, bacteriophage, ribosome, mRNA, yeast, cDNA, 
retrovirus, baculovirus, and mammalian cell display. Bacterial and phage libraries 
are applied for adhesion receptor-binding peptide isolation. In the bacterial 
libraries, peptides are genetically connected to the membrane flagella and fimbriae 
proteins and are displayed on the surface of bacteria. The DNA of the isolated 
bacterial clone is sequenced to reveal the identity of the adhesion receptor-binding 
peptide.88, 89 In the phage display libraries, the DNA sequence of a desired peptide 
is embedded into the DNA of a phage coat protein to encode the peptide. After the 
incubation process, the DNA of the resulting phage is sequenced to discover its 
peptide content.90, 91 Positional scanning synthetic peptide combinatorial libraries 
(PS-SPCLs) and one-bead one-compound (OBOC) libraries are the popular non-
biological libraries for recognition of  adhesion receptor-binding peptides. In OBOC 
libraries, the peptides are synthesized on beads that are approximately 80–100 
μm in diameter; the split mix synthesis method generates the library and after 
incubation of the protein of interest and washing away of the unbound proteins, 
mass spectrometry or Edman’s sequencing determines the peptide content of 
adhesion receptor-binding beads.92, 93 In PS-SPCLs, the peptides are synthesized 
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individually. To synthesize individual peptides, one amino acid is held fixed while 
the remaining amino acids of the peptide vary. Holding a different amino acid 
constant and alternating others creates combinational libraries. There are various 
screening methods for PS-SPCLs such as using specific cellular effects as the 
readout or fluorescent tagging.94 The detailed explanation of each peptide library 
could be the focus of an entire review, and indeed there are many excellent reviews 
about them that we recommend.88, 89, 92-100 These methods have been utilized to 
identify adhesion receptor-binding peptides for other applications than 
regenerative medicine. For example, Table 2.1 shows a selected group of peptides 
from the field of cancer therapy, identified by panning in vivo, OBOC and phage 
display libraries and indicates the feasibility of the proposed methods for identifying 
receptor-binding peptides. 
In summary, the methods of identifying adhesion receptor-binding peptides 
may be an excellent start to recognize bioactive sequences, although further 
investigation would be required to confirm the ability of the sequence to mimic the 
desired binding and to activate the target signaling pathways. 
 
Discussion  
Chondroinductive biomaterials are categorized into two broad groups: 
natural, and synthetic. Natural materials are attractive candidates to be 
incorporated in scaffold structure because they have the potential to communicate 
with cells not only through chemical signaling but additionally through mechanical 
signaling, which is beneficial to tissue-dependent cells. The regenerative 
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properties of natural materials may be attractive for biomaterial design, but their 
disadvantages, such as reproducibility and the risks involved with immunogenicity, 
may complicate regulatory pathways. As a result, natural materials may be less 
attractive for commercialization if 100% synthetic materials are capable of eliciting 
a comparable biological response, which indeed makes designing all-synthetic 
biomaterials a more appealing translational strategy.  
 
The main challenge in designing an all-synthetic biomaterial is to identify 
chemical signals that mimic the adhesion receptor-binding site of ECM or growth 
factors and lead the stem cells to the desired lineage. In the case of cartilage 
regeneration, the cell-ECM signaling is crucial for both chondrocyte survival and 
chondrogenic differentiation. Cell-ECM signaling is mediated by ECM interactions 
with adhesion receptors, namely integrins. Therefore, the integrins expressed by 
chondrocytes and the integrins that change expression during chondrogenic 
differentiation may play a role in mediating cartilage tissue development through 
interaction with ECM. As a result, the ligands specific to these integrins may have 
the potential to provide chemical signals for the cells and to produce 
chondroinductivity. Bioactive peptides are attractive candidates to mimic integrin-
ligand binding because of favorable properties such as reproducibility and low cost.  
 
The integrin-binding peptides, such as RGD, are mainly employed in 
biomaterials for their cell-adhesion properties. In the field of cartilage regeneration, 
a few studies have employed bioactive peptides for their signaling abilities, 
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although none have employed strategies to identify these peptides based on their 
ability to bind to chondrocyte integrins or integrins expressed during chondrogenic 
differentiation.  
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Chapter 3: Effects of a Bioactive SPPEPS Peptide on  
Chondrogenic Differentiation of Mesenchymal Stem Cells 2  
 
Abstract 
A synthetic ‘chondroinductive’ biomaterial that itself could induce 
chondrogenesis without the need for growth factors, extracellular matrix, or other 
pre-seeded cells, could revolutionize orthopedic regenerative medicine. The 
objective of the current chapter was thus to introduce a synthetic SPPEPS peptide 
and evaluate its ability to induce chondrogenic differentiation. In the current 
chapter, dissolving a synthetic chondroinductive peptide candidate (100 ng/mL 
SPPEPS) in the culture medium of rat bone marrow-derived mesenchymal stem 
cells (rBMSCs) elevated collagen type II and aggrecan gene expressions 
compared to the negative control (no growth factor or peptide in the cell culture 
medium) after 3 days. In addition, proteomic analyses indicated similarities in 
pathways and protein profiles between the positive control (10 ng/mL TGF-3) and 
peptide group (100 ng/mL SPPEPS), affirming the potential of the peptide for 
chondroinductivity. Incorporating the SPPEPS peptide in combination with the 
RGD peptide in pentenoate-functionalized hyaluronic acid (PHA) hydrogels 
elevated the collagen type II gene expression of the rBMSCs cultured on top of the 
hydrogels compared to using either peptide alone. The evidence suggests that 
   
2Submitted as: Mahzoon S, Lam TN, Sjoelund V, Detamore MS. Effects of a Bioactive SPPEPS 
Peptide on Chondrogenic Differentiation of Mesenchymal Stem Cell. Annals of Biomedical 
Engineering, 2018. 
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SPPEPS may be a chondroinductive peptide, which may be enhanced in 
combination with an adhesion peptide. 
Introduction 
Cartilage tissue does not have the ability to regenerate on its own. Minor 
injury to cartilage tissue may therefore lead to further degeneration and eventually 
to arthritis, which is the leading cause of disability worldwide. The current surgical 
treatments for cartilage injury such as autologous chondrocyte implantation (ACI), 
microfracture, osteochondral transplantation (mosaicplasty), and allograft 
implants, do not reproducibly lead to tissue with mechanical and structural 
properties comparable to native articular cartilage.3 The failure of current 
treatments to reproducibly regenerate a fully integrated and healthy cartilage tissue 
has motivated the regenerative medicine community to investigate strategies that 
lead to the creation of fully functional hyaline cartilage.1, 2 Cell-based approaches 
may be promising in terms of hyaline cartilage formation, but inherent translational 
challenges motivate the identification of acellular alternatives.3, 4 Acellular 
materials may support chondroinductivity if natural components such as 
extracellular matrix (ECM) molecules or growth factors are added to their structure. 
While natural components may mimic the native cartilage enviroment and be 
chondroinductive, their limitations (e.g., cost, reproducibility, and potential for 
immunogenicity or disease transmission) present challenges for commercial 
adoption. Therefore, an all-synthetic biomaterial, providing chondroinductive 
capabilities without the need for animal-derived components or cells, may offer a 
superior alternative.  
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To regenerate cartilage tissue with an all-synthetic material, the ideal 
scaffolding biomaterial must have mechanical integrity suitable for weight-bearing 
application and the ability to induce chondrogenic differentiation of endogenous 
mesenchymal stem cells (MSCs). The desirable failure properties (e.g., maximum 
stress and strain, and toughness)7 of the material may be achieved via polymer 
selection and composition; identifying all-synthetic cellular signals for 
chondroinduction would then be the remaining challenge. In the field of 
regenerative medicine in general, there are several studies that have aimed to 
identify peptides as signals for cells.8-13 In addition, there are review papers on 
receptor-binding peptides; however, they have not focused on regenerative 
medicine applications.14 
 
The chondroinductivity of synthetic peptides has been explored by a few 
pioneering groups. For example, the Link N peptide was identified as potentially 
chondroinductive in 2003, with 100 ng/mL of the peptide added to the culture 
medium of both nucleus pulposus (NP) and annulus fibrous (AF) cells, elevated 
accumulation of collagen type II and IX (measured by ELISA).15, 19 In 2010, it was 
shown that the GFOGER peptide increased relative gene expressions of aggrecan 
and collagen types II and X of human mesenchymal stem cells encapsulated in 
poly(ethylene glycol) (PEG) hydrogels when the GFOGER peptide was chemically 
incorporated in the hydrogels by Michael additional chemistry.23 The B2A peptide 
with a sequence of (H-AISMLYLDENEKVVLKK(H-AISMLYLDEN-EKVVLK)-Ahx-
Ahx-AhxRKRLDRIAR-NH2)101 was designed in 1999 and consists of a receptor 
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targeting domain, a hydrophobic spacer domain and a heparin-binding domain.24 
In 2012, it was shown that adding 10 μg/mL of the B2A peptide to murine 
embryonic stem cells medium increased Sox9 and collagen type Il gene 
expressions.27 In 2012, the BMP2-mimic peptide sequence (KIPKASSVPTE- 
LSAISTLYL) was added to human MSCs medium (100 ng/mL), which resulted in 
increased Sox9 and collagen type II gene expressions.31 
 
Identifying peptides capable of chondroinduction, and designing 
biomaterials that incorporate them, may lead to 100% synthetic, chondroinductive 
biomaterials – which could be revolutionary in cartilage injury treatment. In the 
current study, we explored the chondroinductivity of a peptide candidate with rat 
bone marrow-derived mesenchymal stem cells (rBMSCs) in 2D culture. The 
peptide was then conjugated to a pentenoate-functionalized hyaluronic acid (PHA) 
hydrogel, and the chondroinductivity of the resultant hydrogels (via 2D culture on 
their surface) was evaluated by real-time quantitative polymerase chain reaction 
(rt-PCR). 
 
We identified the peptide candidate (Ser-Pro-Pro-Glu-Pro-Ser, SPPEPS) as 
a matching sequence of two chondroinductive molecules, aggrecan (a 
proteoglycan found in abundance in cartilage matrix that is known to induce 
chondrogenic differentiation102) and transforming growth factor-3 (TGF-3, known 
to play a major role in cartilage development).103, 104 TGF-3 has 390 to 414 amino 
acids and consists of two polypeptide chains, i.e., C-terminal and N-terminal 
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subunits. The N-terminal subunit is known as the latency-associated protein 
(LAP),105 and the SPPEPS peptide sequence belongs to this LAP region of TGF-
3. It is known that LAP is a ligand for a number of integrins.106-108 It is widely known 
that integrins mediate cell-ECM signaling pathways and play a critical role in 
cartilage regeneration. Moreover, the binding sequences of integrins can be 
duplicated by bioactive peptides and the peptides have the potential to activate the 
desired signaling pathways. Replacing growth factors and extracellular proteins 
with their respective peptide binding sequences may potentially revolutionize the 
field of regenerative medicine, as we recently reviewed in more detail.109  
 
In the current study, the chondroinductivity of the SPPEPS peptide 
sequence was evaluated with rBMSCs when the SPPEPS peptide was coated 
onto the culture surface or was dissolved in cell culture medium at different 
concentrations. For further analysis, the chondroinductivity of SPPEPS was 
evaluated when the peptide was conjugated to PHA hydrogels and rBMSCs were 
cultured on top of the hydrogels. The peptide was conjugated to PHA with or 
without the RGD adhesion peptide. Our hypothesis was that the SPPEPS peptide, 
as a matching sequence found in two chondroinductive molecules (i.e., TGF-3 
and aggrecan), would induce initial chondrogenic differentiation of rBMSCs 
superior to that induced by TGF-3.  
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Methods and Materials 
 
Cell Culture and SPPEPS Peptide Incorporation 
rBMSCs from the tibias and femurs of 8 week-old male Sprague–Dawley Rats 
(ScienCell, Carlsbad, CA) were thawed and cultured to passage 4 in cell culture 
medium (minimum essential medium- (Cat# 12561072, Thermo Fisher Scientific, 
Waltham, MA) supplemented with 10% fetal bovine serum (FBS, Cat# 16000044, 
Thermo Fisher Scientific) and 1% penicillin/streptomycin (Cat# 15140-122, 
Thermo Fisher Scientific)). The cells were used immediately after passage 4. The 
six peptides (Table 3.1) were custom-ordered from Biosynthetic (Lewisville, TX), 
who synthesized the peptides with a PTI Symphony peptide synthesizer (Tucson, 
AZ) using solid-phase synthesis with Fluorenylmethyloxycarbonyl protecting group 
(Fmoc) chemistry, which means Fmoc was used for the temporary protection of 
the N-terminus, and then cleaved from the resin using standard methods. 
Biosynthetic confirmed peptide identities by mass spectroscopy, and purity was 
shown to be >95% using analytical high-performance liquid chromatography 
(HPLC, Shimadzu, Columbia, MD). 
 
In one set of groups, the SPPEPS peptide was adsorbed to the well plate 
surface. The SPPEPS peptide was dissolved in sterile DI water (20 µg/mL), sterile-
filtered (0.22 µm), and added to sterile 96-well tissue culture treated (TCT) plates 
to reach the desired coating concentrations (0.5, 1 and 3 µg/mm2) before overnight 
water evaporation at room temperature in sterile conditions. The rBMSCs were 
thawed and after passage 4 were cultured on the plates at 150,000 cells/well (i.e., 
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23.5 x 106 cells/cm2) with the aforementioned cell culture medium, and the cell 
culture medium was changed every second day. Uncoated TCT plates served as 
the control group.  
 
In a separate set of groups, the SPPEPS peptide was included in soluble 
form in the medium instead of being coated on the surface. rBMSCs were cultured 
on 96-well plates (150,000 cells/well) with cell culture medium containing SPPEPS 
(50, 100 and 500 ng/mL). Fresh peptide was added with every medium change 
every second day. 
 
Description of Experimental Design  
 In a preliminary study, the chondroinductivities of Link N and SPPEPS with 
rBMSCs were evaluated at two plate coating densities (0.5 and 1 µg/mm2) and two 
soluble concentrations (10 and 100 ng/mL) after 3 days by rt-PCR (n=3). The 
chondroinductivity was compared with the negative control (no growth factor or 
peptide in the cell culture medium) and positive control groups. The positive control 
was a known chondrogenic growth factor in lieu of the SPPEPS peptide, i.e., 10 
ng/mL (dissolved in rBMSCs cell culture medium) human transforming growth 
factor-3 (TGF-3, R&D systems, Minneapolis, MN). The collagen type II gene 
expression of SPPEPS 100 ng/mL group was 2.3 times higher than in the control 
group in our preliminary study (p < 0.05) (Fig. 3.8), which led us to further analyses 
on the chondroinductivity of the SPPEPS peptide for 50 to 500 ng/mL peptide 
concentrations in cell culture medium and 0.5 to 3 µg/mm2 coating concentrations.  
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In the current study, rBMSCs were cultured either on TCT plastic or on a 
hydrogel surface. For the cells cultured on TCT plates, three different 
concentrations of SPPEPS peptide (50, 100 and 500 ng/mL) in cell culture 
medium, three different coating concentrations (0.5, 1 and 3 µg/mm2) and a control 
group (no growth factor or peptide in the cell culture medium) were evaluated (n=6) 
and the peptide chondroinductivity was evaluated by rt-PCR after 3 days (see gene 
expression sub-section below). 
 
The 100 ng/mL concentration of SPPEPS was selected for proteomic 
analysis due to its superiority in inducing chondrogenic differentiation (see 
Proteomics sub-section below). Another group of rBMSCs from the same source 
described above (i.e., tibias and femurs of 8 week-old male Sprague–Dawley Rats 
(ScienCell, Carlsbad, CA)) were purchased and the samples were prepared using 
the cell culture methods described above. The positive control was 10 ng/mL TGF-
3 in cell culture medium and the negative control group was a group with no 
peptide or growth factor in the cell culture medium (n=4). All proteomics data were 
normalized to the control. 
 
For the analysis of the rBMSCs cultured on the hydrogel surface, a new group of 
rBMSCs from the same source described above (i.e., tibias and femurs of 8 week-
old male Sprague–Dawley Rats (ScienCell, Carlsbad, CA)) was purchased and 
prepared until passage 4 using the cell culture methods described above. The 
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rBMSCs on tissue culture plates served as the baseline control group and the 
chondroinductivities of PHA hydrogels were analyzed by rt-PCR after 3 days for 
various peptides, which were conjugated to the PHA hydrogel (n=4). A PHA (5% 
(w/v) pentanoate-functionalized hyaluronic acid) group with no peptide conjugation 
(see next sub-section for supplier and synthesis information), along with 
PHA+RGD (PHA conjugated to 1.5 mM GCGYGRGDSPG), PHA+SP (PHA 
conjugated to 1.5 mM GCGYGSPPEPS), PHA+PS (PHA conjugated to 1.5 mM 
GCGYGPSEPSP (scrambled SPPEPS)), PHA+RGD+SP (PHA conjugated to 1.5 
mM GCGYGRGDSPG and 1.5 mM GCGYGSPPEPS) were chosen for analyses. 
The PHA+PS group served as a scrambled sequence control for the PHA+SP 
group. 
 
Synthesis of Pentenoate-Functionalized Hyaluronic Acid (PHA)  
PHA was synthesized as previously described.110 Briefly, hyaluronic acid 
(HA, Mw = 60 kDa, Lifecore Biomedical, Chaska, MN) was fully dissolved in DI 
water to a 5% (w/v) concentration before dropwise addition of dimethylformamide 
(DMF) to reach a 3:2 ratio of water:DMF. Simultaneously, 5M pentenoic anhydride 
(Cat# 471801, Sigma-Aldrich, St. Louis, MO) was slowly added to the solution in 
excess relative to HA. When adding the DMF and pentenoic anhydride was 
complete, the solution pH was maintained at 8-9 by slow dropwise addition of 1M 
NaOH during constant monitoring of the PH for 5 hours. The conjugation reaction 
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was completed overnight to form PHA. The next day, solid NaCl was added to the 
solution to reach the final concentration of 0.5M NaCl. After the salt was fully 
dissolved, the polymer was precipitated by adding acetone (water/acetone (v/v) 
ratio of 1:4) and centrifuging the solution at 7,000 x g for 5 minutes. After 
centrifuging, the PHA was completely precipitated in the form of pellets. The pellets 
were dissolved in DI water and dialyzed against DI water for 48 hours, exchanging 
the DI water every 12 hours. After dialysis, dry PHA was frozen, lyophilized, and 
stored at –20°C. 
 
PHA Hydrogel Preparation, Peptide Conjugation, and Surface 
Analysis 
To prepare PHA hydrogels (without peptide incorporation), a solution of 
phosphate-buffered saline (PBS) containing 2.3 mM 2-Hydroxy-4′-(2-
hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959, Cat# 410896, Sigma-
Aldrich) and 1% dithiothreitol (DTT, Cat# D0632, Sigma-Aldrich) was prepared and 
sterile-filtered (0.22 µm). The PHA was removed from the freezer and brought to 
room temperature and then sterilized using ethylene oxide gas (AN74i, Anderson 
Anprolene, Haw River, NC) and mixed with the PBS solution to reach 5% (w/v) 
PHA concentration. The solution was left at room temperature for 2 hours to fully 
dissolve the PHA particles. 100 µL of this precursor solution was added to each 
well of a 48 well plate and briefly centrifuged before hydrogel crosslinking with a 
handheld 312 nm UV-light at 9 mW/cm2 for 2 minutes (EB-160C, Spectroline, 
Westbury, NY).  
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To prepare PHA hydrogels with conjugated peptides, hydrogels were made 
in two steps. First, PHA was mixed with PBS solution containing 1 mM Irgacure 
and 1.5 mM thiolated peptide to achieve a 2% (w/v) PHA solution. The solution 
was conjugated with UV light for 2 minutes, and the conjugation of the peptide to 
the PHA network was confirmed with H1NMR (Varian Mercury VNMRS 400 MHz 
spectrometer, Fig. 3.9). This solution was then mixed with more PHA (to achieve 
final concentration of 5% (w/v)) and was mixed with PBS solution containing 
Irgacure and DTT to achieve 2 mM Irgacure concentration and 1% w/v DTT. The 
solution was again crosslinked for 2 minutes to create the final hydrogels. rBMSCs 
were cultured with the same methods explained above until passage 4 and then 
were cultured on top of the hydrogels (30,000 cells/well, i.e., 47 x 106 cells/cm2) 
and the medium (minimum essential medium- supplemented with 10% FBS and 
1% penicillin/streptomycin) was changed every second day for 3 days (n=4). 
 
The DNA contents of all the samples (Control, PHA, PHA+RGD, PHA+SP, 
PHA+PS and PHA+RGD+SP) were measured after 3 days (n=4). The samples 
were digested overnight at 65°C in 200 µL papain mixture (125 mg/mL papain from 
papaya latex, 5 mM N-acetyl cysteine, 5 mM EDTA, and 100 mM PBS) and the 
DNA content of the samples was measured using a PicoGreen assay kit (Thermo-
Fisher Scientific, Waltham, MA, P7589) according to the manufacturer’s 
instructions. All the samples were evaluated in triplicate. 
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Gene Expression  
 The gene expressions were analyzed for all the rBMSCs samples cultured 
on the TCT plates after 3 days (n=6) and all the rBMSCs cultured on the hydrogel 
surface after 3 days (n=4). The gene expressions of each sample were evaluated 
in triplicate. To prepare the samples for gene expression, the mRNAs were 
extracted after 3 days using Qiagen RNeasy mini kit (Valencia, CA) following the 
kit instructions, before reverse transcription using a cDNA kit (Invitrogen, Carlsbad, 
CA). rt-PCR was performed with a qTOWER3 Thermal Cycler (Upland, CA) using 
TaqMan Col2A1, Sox9, ACAN and GAPDH primers (Invitrogen, Carlsbad, CA). 
GAPDH was used as an endogenous control, with relative gene expression 
measured using the 2-ΔΔCt method. For cells on both surfaces, the calibrators 
were the rBMSCs at passage 4 before transferring them to the 96-well plates. 
 
Proteomics 
For the proteomics analyses, the samples were prepared at 7 and 14 days 
(n=4). The samples were washed with PBS three times and lysed in 50 µL modified 
RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Na-
deoxycholate and 1% IGEPAL) containing phosphatase inhibitors and protease 
inhibitors (Roche, Indianapolis, IN). The lysates were centrifuged for 10 minutes at 
12,000 g and the supernatant collected for mass spectrometry-based proteomics.  
The protein lysate was subjected to the FASP protocol. Briefly, the 
cysteines were reduced and alkylated and the protein digested overnight with 
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trypsin in 50 mM ammonium bicarbonate. The resulting peptides were dried and 
resuspended in 10 mM ammonium formate pH 10.0. Liquid chromatography 
tandem mass spectrometry was performed by coupling a nanoAcquity UPLC 
(Waters Corp., Manchester, UK) to a Q-TOF SYNAPT G2S instrument (Waters 
Corp., Manchester, UK). Each protein digest (about 100 ng of peptide) was 
delivered to a trap column (300 μm × 50 mm nanoAcquity UPLC NanoEase 
Column 5 μm BEH C18, Waters Corp, Manchester, UK) at a flow rate of 2 μl/min 
in 99.9% solvent A (10 mM ammonium formate, pH 10, in HPLC grade water). 
After 3 min of loading and washing, peptides were transferred to another trap 
column (180 μm × 20 nanoAcquity UPLC 2G-V/MTrap 5 μm Symmetry C18, 
Waters Corp., Manchester, UK) using a gradient from 1% to 60% solvent B (100% 
acetonitrile). The peptides were then eluted and separated at a flow rate of 200 
nL/min using a gradient from 1% to 40% solvent B (0.1% formic acid in acetonitrile) 
for 60 min on an analytical column (7.5 μm × 150 mm nanoAcquity UPLC 1.8 μm 
HSST3, Waters Corp, Manchester, UK). The eluent was sprayed via PicoTip 
Emitters (Waters Corp., Manchester, UK) at a spray voltage of 3.0 kV and a 
sampling cone voltage of 30 V and a source offset of 60 V. The source temperature 
was set to 70 °C. The cone gas flow was turned off, the nano flow gas pressure 
was set at 0.3 bar and the purge gas flow was set at 750 ml/h. The SYNAPT G2S 
instrument was operated in data-independent mode with ion mobility (HDMSe). 
Full scan MS and MS2 spectra (m/z 50 - 2000) were acquired in resolution mode 
(20,000 resolution FWHM at m/z 400). Tandem mass spectra were generated in 
the trapping region of the ion mobility cell by using a collisional energy ramp from 
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20 V (low mass, start/end) to 35 V (high mass, start/end). A variable IMS wave 
velocity was used. Wave velocity was ramped from 300 m/s to 600 m/s (start to 
end) and the ramp was applied over the full IMS cycle. A manual release time of 
500 μs was set for the mobility trapping and a trap height of 15 V with an extract 
height of 0 V. The pusher/ion mobility synchronization for the HDMSe method was 
performed using MassLynx V4.1 and DriftScope V2.4. LockSpray of 
Glufibrinopeptide-B (m/z 785.8427) was acquired every 60 s and lock mass 
correction was applied post acquisition. The data was analyzed with PLGS and 
QIP (Waters Corp., Manchester, UK). Proteomic data were further analyzed using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID, 
https://david.ncifcrf.gov/) through Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis. 
 
Statistical Analyses 
For the statistical analyses, Tukey’s HSD method was used for inter-group 
comparisons, and Dunnett’s test was employed to compare the groups with the 
negative control. Calculations were performed with GraphPad Prism (Graphpad 
Software Inc., La Jolla, CA), with p < 0.05 considered significant. The results for 
rt-PCR and PicoGreen were reported as the mean ± standard deviation, with 
proteomics results reported as median ± standard deviation.  
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Results 
 
DNA Content 
In the hydrogel surface analysis (Fig. 3.1), the DNA contents were in the 
range of 0.8 to 1.1 µg, with 34% and 27% higher DNA contents in the PHA and 
PHA+SP+RGD groups compared to the control (rBMSCs on TCT plates), 
respectively (p < 0.05). In addition, comparing the DNA contents of hydrogel 
groups indicated that the DNA content of the PHA group was 36% and 32% higher 
compared to the PHA+RGD and PHA+SP groups respectively (p < 0.05).   
 
 
Gene Expression  
In the preliminary study, the collagen type II gene expression of SPPEPS 
100 ng/mL group was 2.3 times higher than in the control group (p < 0.05) (Fig. 
3.8), which led us to further analyses on the chondroinductivity of the SPPEPS 
peptide. In the current study, for the rBMSCs on TCT plates, the Sox9 gene 
expression from control group was 4.0, 4.2, and 4.5 times higher than all of the 
coating groups (SPPEPS 0.5, 1 and 3 µg/mm2), respectively (p < 0.05). Comparing 
the Sox9 gene expressions of the peptide groups indicated that the Sox9 gene 
expressions of SPPEPS 50 and 500 ng/mL groups were 4.5 - 5.2 times and 3.2 - 
3.6 times higher than SPPEPS 0.5, 1 and 3 µg /mm2 groups, respectively (p < 
0.05) (Fig 3.2). The collagen type II gene expressions from SPPEPS 0.5, 1 and 3 
µg/mm2 and SPPEPS 100 ng/mL groups were 61, 74 and 75% lower and 1.5 times 
higher than in the control group, respectively (p < 0.05). Collagen type II gene 
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expressions from peptide-in-medium groups (i.e., SPPEPS 50, 100 and 500 
ng/mL) were 2.5 to 6.5 times higher than peptide-coating groups (i.e., SPPEPS 
0.5, 1, 3 µg /mm2) (p < 0.05). In addition, collagen type II gene expression from 
SPPEPS 100 ng/mL group was 1.5 and 1.6 times higher compared to SPPEPS 50 
and 500 ng/mL, respectively (p < 0.05) (Fig. 3.2). No other differences in collagen 
II gene expressions were statistically significant. The aggrecan gene expressions 
from SPPEPS 3 µg/mm2, and 50, 100 and 500 ng/mL groups were 31, 34, 35, 31% 
higher compared to the control group, respectively (p < 0.05) (Fig. 3.2). There were 
not any other significant differences among the groups. 
 
In the hydrogel surfaces study, the Sox9 gene expressions from the 
hydrogel groups were 20 to 100 times higher than from the TCT plate group, 
although none of the differences were significant (Fig. 3.3). The combined effect 
of the SPPEPS and RGD peptides was especially evident in collagen II gene 
expression, as the collagen type II gene expression from the PHA+SP+RGD group 
was 300 times higher compared to the TCT plate group and 3 to 7 times higher 
compare to the PHA, PHA+RGD, PHA+SP and PHA+PS groups, respectively (p 
< 0.05). There were no other significant differences among the collagen type II 
gene expressions, although the collagen type II gene expressions of the PHA, 
PHA+RGD, PHA+SP and PHA+PS groups were 40 to 90 times higher than TCT 
plate group (Fig. 3.3). Interestingly, the aggrecan gene expression of TCT plate 
group was 2.6 times higher than PHA+PS group (p < 0.05) (Fig. 3.3). There were 
no other significant differences among the gene expressions. 
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Proteomics analysis 
The proteomics data monitored the expression of 1446 proteins in each 
group (positive TGF-β3 control, negative control and SPPEPS: days 7 and 14). In 
the positive control day 7, SPPEPS day 7, positive control day 14, and SPPEPS 
day 14, there were 248, 132, 206 and 148 proteins with higher expression levels 
compared to the negative control, respectively (p < 0.05), and there were 192, 297, 
166 and 127 proteins with a lower expression level compared to the negative 
control, respectively (p < 0.05) (Fig. 3.4). Among the hundreds of upregulated 
proteins, there were 60 common proteins to both the SPPEPS and positive control 
groups at day 7 (p < 0.05). KEGG pathway analysis of these 60 proteins indicated 
that the “Insulin Signaling Pathway” was activated through the GSK-3 gene (Fig. 
3.7). GSK-3 has been identified to be an essential gene for early stage 
chondrocyte differentiation.111 In addition, this gene participates in regulation of 
Wnt/β-Catenin signaling,112 which is a key player signaling pathway for cartilage 
development.113 Among the 60 common upregulated proteins, collagen type XIα1 
was identified as well, which plays a critical role in cartilage formation (Fig. 3.6).114 
At day 14, 26 common proteins were upregulated in both the positive control and 
SPPEPS groups (p < 0.05) (Fig. 3.5). Gene ontology analysis of these 26 proteins 
with DAVID indicated the upregulation of the ENPP1 gene, which is shown to be 
expressed by chondrocytes.115 In addition, the CLIC4 gene was upregulated, 
which plays an important role in the regulation of TGF signaling.116 
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Discussion 
This is the first study to introduce the amino acid sequence SPPEPS as a 
potentially chondroinductive peptide. Supportive evidence included the higher 
expression of collagen II and aggrecan genes with 100 ng/mL of soluble SPPEPS 
on TCT plates compared to the negative control. Coating the TCT plate surface 
with SPPEPS was a less effective method than including in soluble form for 
promoting chondrogenesis, as the only gene upregulation compared to the 
negative control was aggrecan for the 3 µg/mm2 group. This difference in response 
due to method of presentation may be dose-dependent, and/or might have been 
due to temporal variability for gene expression for peptide in medium vs. peptide 
as plate coating.  
 
The SPPEPS (100 ng/mL) group was chosen for proteomics analysis due 
to superior chondroinductivity and consistent patterns of inducing higher collagen 
type II gene expression for rBMSCs compared to the negative control and inducing 
higher expression of aggrecan gene for rBMSCs compared to the negative control. 
Our use of proteomics represents a powerful advance in the analysis of such 
phenomena, providing a better understanding of changes that occur in cellular 
pathways and the whole profile of the proteins when the peptide is introduced to 
cell culture medium.  
 
With the databases available, there are many different methods to analyze 
the proteomics data and to infer more information regarding cellular profiles. In the 
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current study, we performed data analysis with DAVID on the common proteins 
among the study groups that expressed at significantly higher levels compared to 
the negative control. At 7 days, the activation of “Insulin Signaling” pathways 
through an essential gene for cartilage development (i.e., GSK-3) in both the 
positive control and SPPEPS groups in addition to the upregulation of collagen 
type XIα supported the potential of the SPPEPS peptide in regulating cartilage 
regeneration. In addition, 60 of the 132 proteins that were expressed higher in the 
SPPEPS group (compared to the negative control) were expressed in the positive 
control, indicating similarities of protein expression in both groups. However, 72 
proteins were expressed in the SPPEPS group, but not in the positive control, 
indicating the necessity of further analysis to clarify the effects of these proteins on 
other cellular functions. 
 
Among the 26 common upregulated proteins in both of the groups at 14 
days, the upregulations of ENPP1 and CLIC4 genes and their role in chondrocyte 
differentiation and regulation of TGF signaling, respectively, indicated promising 
potential for the SPPEPS peptide in terms of inducing chondroinductivity. At 14 
days, the increased expression of 26 common proteins, in both the positive TGF-
β3 and the SPPEPS groups, may be consistent with the SPPEPS peptide inducing 
chondroinductivity; however, 122 of the 148 higher-expressed proteins in the 
SPPEPS group were not changed in the TGF-β3 positive control, and thus once 
again more investigation is required regarding the perhaps unintended effects of 
the SPPEPS peptide on other cellular functions.  
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For the positive control, 188 of the 248 proteins at day 7 and 180 of the 206 
proteins at day 14 have not been detected in the SPPEPS peptide groups. This 
indicates that the peptide alone cannot completely replace TGF-3, which may be 
a positive finding if deleterious effects are avoided. Therefore, future research is 
required to identify additional chondroinductive sequences and to study their 
synergistic effects on chondrogenic differentiation.  
 
In the hydrogel surface analysis, both Sox9 and collagen type II gene 
expressions of all the hydrogel groups were 20 to 300 times higher compared to 
the TCT groups, which indicated the high impact of PHA for chondroinductivity 
whether the peptides were conjugated to the hydrogel or not. Although the 
differences were not identified as significant (except collagen type II gene 
expression for PHA+RGD+SP compared to the TCT plate group) in statistical 
analysis, because of the low sample number in the study, the data still emphasize 
the high impact of PHA on chondrogenic differentiation. One of the most striking 
findings of the study was that the collagen type II gene expression for the PHA 
group containing both the RGD adhesion peptide and the experimental SPPEPS 
peptide was 3 to 7 times higher than all the other PHA groups, including those with 
the RGD or SPPEPS alone, which suggests that synergistic adhesion and 
differentiation peptides may be an attractive general area of investigation for 
chondrogenic differentiation.  
 
 
46 
Conclusion 
This chapter demonstrated the potential chondroinductivity of the SPPEPS 
peptide, supported by gene expression in different settings and by proteomic 
analysis in response to soluble peptide. Adding the SPPEPS peptide (identified as 
a matching sequence of two chondroinductive molecules) to the cell culture 
medium of rBMSCs led to a significant increase of chondrogenic markers. 
Although our results support the potential of the SPPEPS peptide in cartilage 
regeneration, we acknowledge that proteins were identified that were expressed 
in the positive control but not in the peptide group, and likewise proteins expressed 
in the peptide group but not in the positive control, which indicates that the peptide 
alone cannot exactly mimic TGF-β3. Although the proteomics analysis was not 
performed for the hydrogel-surface culture, the gene expression data indicate the 
high potential of the hydrogels when both the RGD adhesion peptide and the 
SPPEPS peptide were conjugated in inducing enhanced chondroinductivity. 
Overall, the opportunity to identify chondroinductive peptides is an exciting 
burgeoning area of investigation in orthopedic regenerative medicine, with 
SPPEPS being an attractive candidate for future investigation.   
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Chapter 4: Chondroinductive Peptide in Hyaluronic Acid 
Hydrogels for Hyaline Cartilage Regeneration3 
 
Abstract 
  The primary challenge in cartilage regeneration is regenerating true hyaline-
like cartilage. Acellular biomaterials have advantages compared to cell-based 
therapies including a single surgical procedure and cost savings but are generally 
limited in their ability to achieve true hyaline cartilage. We therefore endeavor to 
identify biomaterials that are themselves inherently chondroinductive, without the 
need for extracellular matrix, growth factors or exogenous cells. In the current 
study, our hypothesis was that incorporation of a bioactive SPPEPS peptide into a 
hyaluronic acid hydrogel would provide superior cartilage regeneration compared 
to unadulterated hydrogels. For this purpose, thiolated RGD or thiolated SPPEPS 
(matching peptide sequence of aggrecan core protein and transforming growth 
factor-beta 3 (TGF-3)) peptides were conjugated to pentenoate-functionalized 
hyaluronic acid (PHA). The resultant hydrogels were implanted into defects in the 
femoral condylar cartilage of rabbits before photocrosslinking with UV light. After 
12 weeks, although differences in gross morphological scoring were not 
statistically significant, the SPPEPS peptide indicated the potential of inducing 
chondrogenic differentiation based on the strong collagen II immunostaining and 
cell morphology relative to the PHA-only control. The collagen II production and 
   
3 To be Submitted as: Mahzoon S, Kalvacherla V, Kiyotake EA, Thomas EE, Bowlin BW, Haleem AM 
Detamore MS. Chondroinductive Peptide in Hyaluronic Acid Hydrogels for Hyaline Cartilage 
Regeneration 
, Biomaterials, 2018. 
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evidence of rudimentary columnar organization of chondrocyte-like cells in lacunae 
in the SPPEPS group supported our hypothesis and encourage future exploration 
of synthetic chondroinductive peptides for orthopedic regenerative medicine. 
  
Introduction  
There are several treatments that aim to repair or regenerate injured 
cartilage, such as autologous chondrocyte implantation (ACI), microfracture, 
osteochondral transplantation (mosaicplasty), and allograft implants, but none 
have successfully, unequivocally, and reproducibly produced tissue with the 
mechanical and chemical properties of hyaline cartilage.3 In recent years, different 
regenerative medicine approaches have aimed to produce hyaline-like cartilage 
tissue; however, their translational limitations have not created a comprehensive 
business model to develop across the board technologies.3, 4, 117 The key 
limitations such as high cost associated with the use of stem cells and regulatory 
challenges associated with the use of animal-derived growth factors or 
extracellular matrix (ECM) components, has inspired us to aim to develop acellular 
strategies without the use of animal-derived components by incorporating 
bioactive signals in the structure of biomaterial scaffolds.1, 2 Our unpublished in 
vitro work has suggested that a new SPPEPS peptide may have the ability to 
induce chondrogenesis, i.e., to possess chondroinductive character, which we 
endeavored to evaluate in vivo in the current study. 
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In recent years, a precious few studies have examined the in vivo bioactivity 
of peptides in terms of chondroinductivity. For example, Link N peptide at a 
concentration of 10 mg/mL was injected into 5 mm deep annular punctures in the 
center of the nucleus pulposus (NP) of New Zealand White rabbit intervertebral 
discs (IVDs), and aggrecan expression for both NP and annulus fibrous (AF) cells 
increased after 2 weeks.19 In another study, 500 ng B2A peptide with a sequence 
of (H-AISMLYLDENEKVVLKK(H-AISMLYLDEN-EKVVLK)-Ahx-Ahx-AhxRKRLD- 
RIAR-NH2) was injected into the synovial space of the knee joint of rats with 
osteoarthritis (chemically induced). The authors concluded that B2A enhanced 
cartilage repair after 21 days according to Alcian Blue and H&E histological 
analyses.27 
 
In the current study, we identified SPPEPS as a potentially 
chondroinductive peptide given that it is a matching amino acid sequence of the 
aggrecan core protein and transforming growth factor-beta 3 (TGF-3), both of 
which are known to play roles in chondrogenesis. Here, we conjugated the 
SPPEPS peptide to a pentenoate-functionalized hyaluronic acid (PHA) hydrogel 
network. PHA hydrogels are attractive for surgical application due to their faster 
crosslinking time (1-2 minutes) compared to other hyaluronic acid-based 
hydrogels.110, 118, 119 In addition, hyaluronic acid nanoparticles (HAnp) were 
incorporated into the hydrogels to increase the hydrogel precursor yield stress for 
surgical placement.120 The performance of the PHA hydrogels with conjugated 
SPPEPS were compared in regeneration of rabbit femoral condylar cartilage 
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defects to PHA hydrogels alone (negative control) and to PHA hydrogels 
conjugated with the well-known RGD adhesion peptide.  
 
The goal of the current study was to design a biomaterial that could induce 
hyaline-like cartilage production by guiding chondrogenic differentiation of 
endogenous bone marrow-derived mesenchymal stem cells (BMSCs) without the 
need to harvest/seed cells of any kind or to incorporate any growth factors. Our 
hypothesis was that the SPPEPS peptide in PHA hydrogels would lead to a more 
hyaline-like cartilage tissue compared to PHA hydrogels alone.  
 
 
Materials and Methods 
Synthesis of Hyaluronic Acid Nanoparticles (HAnp) 
HAnp were made by utilizing carbodiimide crosslinking chemistry, which is 
further explained elsewhere.121 Briefly, 300 mg HA (MW = 16 KDa, Lifecore 
Biomedical, Chaska, MN) was dissolved in 120 mL DI water, and then after the HA 
was fully dissolved, 200 mL acetone was added. 60 mg adipic acid dihydrazide 
(AAD) and 140 mg 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
(EDC) (Thermo Scientific, Rockford, IL) were each dissolved in 1 mL DI water and 
were then added to the solution after 15 and 10 minutes, respectively. After 20 
minutes, 200 mL acetone was added to the solution. The reaction was completed 
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in 3 hours. The solution was dialyzed against DI water for 2 days, frozen, 
lyophilized and stored at –20°C. 
Synthesis of Pentenoate Functionalized Hyaluronic Acid (PHA)  
PHA was prepared as our group has described previously.110 Briefly, 5% 
(w/v) solution of HA (MW = 60 KDa, Lifecore Biomedical) in DI water was prepared, 
DMF was added to the solution to reach a water to DMF ratio of 3:2 while pentenoic 
anhydride (Cat# 471801, Sigma-Aldrich, St. Louis, MO) was slowly added to the 
solution in 5 M excess relative to HA. The pH of the solution was monitored for 5 
hours and was maintained at pH 8-9 by adding 1M NaOH to the solution. The 
reaction was completed overnight. NaCl was added to the solution to reach 0.5M 
concentration of NaCl, and the polymer precipitated by adding 4 volumes of 
acetone and centrifuging for 5 minutes (7,000 x g). The precipitated PHA was 
dissolved in DI water and dialyzed for 48 hours. The final product was 17% 
functionalized with the pentenoate group in relation to the repeating disaccharide 
unit. Functionalization was confirmed with 1H-NMR (Varian Mercury VNMRS 500 
MHz spectrometer, Fig. 4.9) by comparing the integration of the alkene peaks on 
the functional group to the acetyl methyl group on the HA. PHA was frozen, 
lyophilized, and stored at –20°C.  
 
Hydrogel Preparation  
The hydrogel precursor material was prepared the day before the surgery. 
PHA was sterilized using ethylene oxide gas (AN74i, Anderson Anprolene, Haw 
River, NC). A solution of 2.3 mM 2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropio- 
52 
phenone (Irgacure 2959, Cat# 410896, Sigma-Aldrich) and 1% dithiothreitol (DTT, 
Cat# D0632, Sigma-Aldrich) was prepared in phosphate-buffered saline (PBS) and 
was sterile-filtered. To prepare the hydrogels in the PHA group, PHA and HAnp 
were added to the PBS solution to make a 5% (w/v) concentration of each. To 
incorporate peptides (i.e., SPPEPS or RGD) in the hydrogel network, a solution 
with concentration 2% (w/v) PHA and 5% (w/v) HAnp was made by adding PHA 
and HAnp to PBS solution containing 1 mM Irgacure and 1.5 mM thiolated 
SPPEPS or thiolated RGD. The solutions were fully dissolved (2 hours) and the 
peptides were conjugated to the PHA after exposure to 312 nm UV light (EB-160C, 
Spectroline) for 2 minutes. Afterward, the solutions were mixed with additional PHA 
and PBS solution containing Irgacure and DTT to achieve the final concentrations 
of 5% (w/v) PHA, 2 mM Irgacure and 1% DTT. When the PHA and HAnp were 
completely dissolved (2 hours), the solutions were pipetted into sterile syringes, 
protected from light with tin foil, and kept sterile until the surgery. Thiolated 
peptides were custom-ordered (Biosynthetic, Lewisville, TX) and synthesized on a 
PTI Symphony peptide synthesizer (Tucson, AZ). Each peptide’s purity was shown 
to be >95% using analytical high-performance liquid chromatography (HPLC, 
Shimadzu, Columbia, MD). 
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Description of Experimental Groups 
In the current study, four different study groups were investigated (n=6). In 
all the groups, defects were created in the medial femoral condyles, and three 
holes were microdrilled into the subchondral bone. In the sham control group, no 
material was placed in the defect. The other groups were the PHA, PHA+RGD and 
PHA+SP groups (i.e., 5% PHA+5% HAnp, 5% PHA+5% HAnp containing 1.5 mM 
RGD, and 5% PHA+5% HAnp containing 1.5 mM SPPEPS, respectively).  
 
Surgical procedure 
All animal experiments were approved by the Institutional Animal Care and 
Use Committee of the University of Oklahoma Health Sciences Center (Protocol # 
17-007-SS A). 12 female New Zealand white rabbits, each 6 months old and 
between 4 to 4.5 kg (Robinson Service, Inc (RSI), Mocksville, NC), were monitored 
for normal and healthy behavior a week prior to the surgery. Following analgesic 
delivery, stable general anesthesia, and antibiotic administration, the area around 
each knee was shaved and prepared (including 3 rounds of alternating 
chlorhexidine scrub and alcohol solution with a final betadine spray). Before the 
procedure, lactated ringers injection (LRS) was provided at multiple injection sites 
around the neck and shoulders to ensure proper hydration and to maintain blood 
pressure. After surgical anesthesia was established, the rabbits were laid in the 
supine position and a medial parapatellar incision was made sufficient to allow 
exposure of the medial femoral condyle. The tibia was lightly pushed to displace it 
54 
laterally to allow the exposure of the medial femoral condyle, and an osteochondral 
defect of 3.5 mm diameter was drilled in the medial femoral condyle cartilage with 
the depth of 1-2 mm, essentially a full-thickness cartilage defect that penetrated 
into subchondral bone. An initial pilot defect was created with a 1 mm drill bit, and 
gradually enlarged to a 3.5 mm defect using 2 and 3.5 mm drill bits. The joint was 
washed of debris with sterile saline before three smaller holes (0.4 mm diameter) 
were microdrilled into the subchondral bone of the defect area to mobilize local 
bone marrow to the site of cartilage lesion. Before placing the hydrogels, the blood 
in the defect was removed with sterile gauze. The hydrogel precursor material was 
placed in the defect area with a syringe and a needle and exposed to 312 nm UV-
light at 9 mW/cm2 (EB-160C, Spectroline) for 5 minutes to form a crosslinked 
network (Fig. 4.1). The joints were washed with sterile saline, and the articular 
capsule and bursae were closed with absorbable suture before binding of the skin 
with intradermal absorbable suture. The rabbits were placed on a recirculating hot 
water blanket during anesthesia and recovery and use of analgesic agents 
continued for 3 days after the surgery. Rabbit sternal recumbency was monitored 
until they could rest unassisted in their home cage. 
 
Post-surgical Care 
After both knee procedures were finished, rabbits were returned to their 
cages and their knee joints were allowed unconstrained post-operative movement. 
Each rabbit’s condition was monitored to detect post-operative complications. 
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Animals were examined three times a day for the first 3 days, once a day for 7 
days, and every other day for the remaining 10.5 weeks to ensure that they 
exhibited normal patterns of behavior, were active and inquisitive, had normal 
posture and movements, and were eating and drinking. Physical examinations 
were performed to look for signs of infection or distress. All the rabbits displayed 
normal behavior one day after the surgery and no signs of inflammation were 
observed, except for rabbit #04, who had inflammation of the left knee (PHA group) 
after surgery, but fully recovered within 5 days.  
 
Gross Morphological Assessment 
The animals were euthanized after 12 weeks by intravascular 
administration of concentrated barbiturate (200 mg/kg) in an ear vein after 
isoflurane anesthesia via masking (as approved by the IACUC protocol). The 
depth of anesthesia was analyzed by measuring heart rate, respiration rate, and 
pedal withdrawal. After the joint retrieval, the knees were photographed. Gross 
morphology was assessed from the images by three independent scorers. The 
scoring criteria were developed from the ICRS scoring chart 122 (Table 4.2), based 
on edge integration of the boundaries of regenerated tissue and native cartilage, 
smoothness of the repair surface, degree of filling at the cartilage surface, color of 
the regenerated cartilage, and the percent of repair tissue relative to the total area. 
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Histological Preparation and Staining  
After joint retrieval, knees were placed in formalin for 36 hours and then 
decalcifying solution for 48 hours (Cat # P7589, Richard-Allan Scientific™ 
Decalcifying Solution, Thermo Fisher Scientific, Waltham, MA), before samples 
were washed in running water for 1 hour. The embedding, sectioning, and staining 
of tissue was performed by the Tissue Pathology Core at the University of 
Oklahoma Health Sciences Center. Briefly, the tissues were embedded in paraffin 
and sectioned to a thickness of 4 to 8 µm before mounting on positively charged 
slides. The slides were dried overnight at room temperature and incubated at 60°C 
for 45 minutes. Staining with Hematoxylin & Eosin or Alcian Blue (Cat # 3801571, 
3801616, 38016SS3DG, Leica Biosystems, Wetzlar, Germany) was performed 
utilizing a Leica ST5020 Automated Multistainer following manufacturer protocols. 
The stains were scored blindly by three different scorers base on the grading 
system described in Table 4.3. 
 
Immunohistochemistry 
The slides were processed similar to the basic histology as described above 
up through incubation in 60°C for 45 minutes. The slides were cleared with xylene 
for 10 minutes and slowly rehydrated in 100%, 95%, and 70% ethanol for 4, 3, and 
3 minutes respectively. After incubating the slides in distilled water (dH2O) for 3 
minutes, the sections were exposed to 0.3% hydrogen peroxide solution (Cat # 
ab94666, Abcam, Cambridge, MA) for 30 minutes to suppress endogenous 
peroxidase activity. The slides were soaked in PBS+Tween (Cat # P3563, Sigma 
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Aldrich, St Louis, MO) for 5 minutes and were incubated in proteinase K (Cat # 
ab64220, Abcam) for 15 minutes in 37°C and 10 minutes in room temperature and 
then were soaked in PBS tween for 5 minutes. Sections were blocked first with a 
sequence of Avidin and then Biotin blocking solutions (Cat # SP-2001, Vector 
Laboratories, Burlingame, CA) each 15 minutes, and then with 3% blocking horse 
serum (Cat #S-2012, Vector Laboratories) for 20 minutes. The collagen type II 
primary antibody (Cat # 08631711, MP Biomedicals, CA, USA, dilution 1:150) 
incubation followed for 1 hour at room temperature and then overnight at 4°C. The 
next day, the slides were soaked in PBS+Tween for 5 minutes and were exposed 
to horse anti-mouse IgG biotinylated secondary antibody and ABC reagent (Cat 
#PK-6102, Vector Laboratories) for 60 and 30 minutes, respectively. Visualization 
was accomplished with ImmPact DAB peroxidase substrate (Cat #SK-4100, 
Vector laboratories) followed by exposure to DAB enhancing solution (Cat #H2200, 
Vector laboratories) and then Hematoxylin QS solution (Cat #H-3404, Vector 
Laboratories) for 10 seconds and 1 minute, respectively. The slides were 
dehydrated in graded ethanol, cleared in xylene and mounted (Permount, SP15-
500 Fair Lawn, NJ). 
 
Statistical Analyses 
The data are shown as mean ± standard deviation where applicable. The 
statistical analyses were performed using ANOVA followed by Tukey’s HSD 
method for comparisons (Graphpad Software Inc., La Jolla, CA), the statistical 
significance threshold was 0.05 in all the analyses (i.e., p < 0.05). 
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Results 
Gross Morphological Observations 
At the time of tissue retrieval, visual inspection revealed no signs of 
inflammation, swelling, or redness at the defect sites and joint surfaces (Fig. 4.2). 
The percentage of the repaired tissue for the control group was between 56 and 
100% (average 86 ± 16%), between 30 and 98% for the PHA group (average 74 ± 
22%), between 26 and 100% (average 84 ± 26%) for the PHA+RGD group, and 
between 15 and 100% (average 74 ± 35) for the PHA+SP group. No statistically 
significant differences were detected among the groups (Fig. 4.3). The gross 
morphological scores (Fig. 4.3), where 10 represents the highest quality of 
regeneration (Table 4.2), were between 4 and 9 (average 7.8 ± 1.9) for the control 
group, between 2.6 and 8.6 (average 6.2 ± 2.1) for the PHA group, between 1.6 
and 10 (average 7.6 ± 3.2) for the PHA+RGD group, and between 1.3 and 8.6 
(average 5.6 ± 3.2) for the PHA+SP group. PHA+RGD was the only group that had 
condyles (6R and 8L) with a total score of 10 out of 10 for gross morphology. 
 
Histomorphometric Observations 
The morphometric analyses of the H&E staining indicated that in 50% of the 
condyles from the control group, the cells were mostly chondrocytes, 33% of the 
defects had mixed chondrocytes and fibrocartilage differentiated in the cartilage 
zone and 17% had mostly fibrocartilage appearance. For the PHA group, we 
observed that 17% of the defects had mostly chondrocytes, 50% had mixed 
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chondrocytes and fibrocartilage and 33% had mostly fibrocartilage. In the 
PHA+RGD group, for 17% of the condyles, most of the cells in the defects were 
chondrocytes; for 67% of the defects, the cells were a mix of fibrocartilage and 
chondrocytes; and 17% of the defects mostly had a fibrocartilage appearance. In 
the PHA+SP group, the cells were mostly chondrocytes in 33% of the defects. We 
observed a mix of fibrocartilage and chondrocytes in 50% of the defects, and 
mostly fibrocartilage in 17% of the defects.  
 
The scoring of the cartilage thicknesses indicated that the cartilage 
thicknesses of 17% of the condyles from the control group were similar to the 
surrounding native cartilage, for 50% and 33% of the condyles the cartilage 
thicknesses were greater and less than the healthy cartilage, respectively. For the 
PHA group 33% of the condyles showed no cartilage thickness, 17% had greater 
cartilage thicknesses compared to the surrounding tissue, and 50% had smaller 
cartilage thicknesses compared to the surrounding. The cartilage thicknesses in 
the defect areas of PHA+RGD condyles were greater than the surrounding for 50% 
of the defects and less than the surrounding cartilage for the rest. 17% of the 
condyles from the PHA+SP group had cartilage thicknesses similar to the 
surrounding cartilage. The cartilage thicknesses were greater and less than the 
surrounding cartilage for 17% and 66% of the condyles, respectively.  
 
In the condyles of the control group, 66%, 17%, and 17% had edge 
integrations on both ends, on one end, and on neither end, respectively. In the 
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PHA group, 33%, 50%, and 17% of the condyles had cartilage integrations on both 
ends, on one end, and on neither end, respectively. The integrations of the 
regenerated tissues were at the both ends for 33% and at one end for 67% of the 
knees for PHA+RGD condyles. 50% of the defect integrations were at both sides 
and the rest were integrated on one side in the PHA+SP condyles. 
 
The scoring of the regenerated subchondral bone in the defect areas 
indicated that 50% of the condyles from the control group showed normal 
subchondral bone regeneration. 33% and 17% of the condyles had reduced and 
minimal reconstruction of subchondral bone compared to the native surrounding 
tissue, respectively. In the PHA group, 33% of the samples showed no 
subchondral bone reconstruction, 17% of the condyles had normal reconstruction 
of subchondral bones compared to the surrounding tissue, and 50% of them 
showed no reconstruction of the subchondral bone. In the PHA+RGD group, 17%, 
50%, and 33% of the condyles had normal, reduced, and minimal reconstruction 
of subchondral bones, respectively. In the PHA+SP group, for 50% of the condyles, 
the reconstruction of the subchondral bones appeared normal, and for the rest of 
the knees the reconstructed bones were reduced compared to the surrounding 
tissue.  
 
In the control group, the Alcian Blue staining of the knees was intense for 
the 2R, 3L and 11R condyles, whereas the regenerated cartilage in the 1L, 10L 
and 12R condyles did not stain intensely (Fig. 4.6). From the morphometric score 
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distribution (Fig.4. 4), we observed that 50% of the knees were normally stained 
and 50% were moderately stained. In the PHA group, we did not observe any 
intense Alcian Blue staining, 50% of the condyles had moderate staining and 50% 
of them had slight staining. In the Alcian Blue staining of the PHA+RGD group, we 
observed that the 8L condyle had normal staining (i.e., similar to healthy tissue) in 
the defect area and the rest of the condyles had slight or moderate staining. The 
scoring of the PHA+SP group indicated that 50% of the condyles had normal 
staining, 17% of them had moderated and 33% had slight staining. 
 
Collagen II Immunostaining 
 In the control group, collagen II staining was prevalent with intensity similar 
to the surrounding cartilage tissue for the 2R and 3L condyles. In the rest of the 
control group condyles, the collagen II immunostaining did not cover the whole 
cartilage region of the regenerated tissue. The 1L and 10L condyles had some 
staining at the edges of the defects. In the 11R condyle, the staining was not 
observed at the cartilage surface, and the 12L condyle had mild staining at parts 
of the cartilage-bone border (Fig. 4.7). Furthermore, closer observation indicated 
that in the 2R and 3L condyles, columnar lacunae formations were observed, 
although in the cartilage zone of the 3L condyle, several fibrocartilage cells clusters 
were observed where no collagen II staining was present (Fig. 4.8).  
 
For the PHA group, the collagen II staining was slight in the defect areas of 
the 1R, 5R, and 8R condyles, and the staining in the 10R, 7L, and 4L condyles 
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was observed at the edges of the defects (Fig. 4.7). In addition, the 4L condyle 
had a small patch of collagen II staining in the middle of the defect. Closer 
observation of the defects indicated that the regenerated tissues of the 5R and 8R 
condyles had some lacunae in the defect site, but with a poor cartilage and bone 
structure (Fig. 4.8). All the defects of the PHA+RGD group had non-prevalent 
collagen II staining, although the stained regions of the 8L and 9R condyles had 
the same stain intensity as their surrounding healthy cartilage. The collagen II 
immunostaining in the 5L and 11L condyles was present at the edges of the defects 
but not in the center, and staining in the 6R condyle was only observed in the 
cartilage-bone boarder. For the 2L, 8L, and 9R condyles, no staining was observed 
at the cartilage surface.  
 
The most prevalent collagen II immunostaining was in the PHA+SP group. 
From this PHA+SP group, the 3R, 7R, and 9L condyles especially had prevalent 
collagen II staining, and the intensities were the same as the surrounding cartilage. 
Staining in the 6L and 12R condyles was only observed in the cartilage-bone 
border and at the center of the regenerated tissue, respectively. The 4R condyle 
staining was observed as a small patch in the middle of the defect. Closer 
observation of the defects (Fig. 4.8) indicated that the lacunae of the 3R and 7R 
condyles had some columnar formations but not in all the defect region. The 
staining for the 7R condyle was intense around several clustered columnar 
lacunae (Fig. 4.8).  
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Discussion 
The current study was the first time that potential chondroinductivity has 
been demonstrated in vivo by conjugating/immobilizing a peptide sequence to a 
biomaterial implant for cartilage regeneration. Specifically, the potential of 
PHA+SP hydrogels in developing a hyaline-like tissue as an acellular technology 
was demonstrated without the need for exogenous cells, growth factors, or 
human/animal-derived extracellular matrix, supporting the hypothesis of the study. 
 
The fact that 66% of the knees had >80% regeneration in the defect 
indicated good regeneration rate in the majority of the condyles, which may be due 
to microdrilling of the defects and BMSCs infiltration to the defects. The lower 
regeneration rates in some of the condyles could potentially be due to mechanical 
failure of the hydrogel, for example an anomaly due to a particular individual 
rabbit’s physical stress placed on the material. Another possibility for variations in 
healing may be the variations in surgical technique, as a full-thickness chondral-
only defect with a 3.5 mm diameter was difficult with the natural curvature of the 
femoral condyle surface, and so there may have been some variation in the extent 
of subchondral bone disruption. In addition, microdrilling of course resulted in 
bleeding of the defect, which in turn caused expected difficulties in placing the 
hydrogel precursor into the defect. Although the blood was removed with sterile 
gauze, mixing of blood and the hydrogel precursor material occurred in some of 
the samples, which changed the fluid mechanics of the hydrogel precursor prior to 
64 
crosslinking. This limitation can be avoided by increasing the percentage of HAnp 
to produce more paste-like precursor solutions.120  
 
Incorporation of the peptides (PHA+SP and PHA+RGD) elevated the 
structural integrity of the regenerated cartilage compared to PHA group. However, 
a significant finding was the poorer collagen II production in the PHA+RGD group 
relative to the PHA+SP group, which was likely due to the fact that although RGD 
encourages cellular adhesion, it does not provide any chondrogenic-specific signal 
in the absence of chondrogenic growth factors.72, 123 
 
Creating true, functional hyaline cartilage has been the elusive goal of 
cartilage regeneration community, and there are indeed a small handful of 
approaches in the literature that have evaluated a hyaline-like tissue regeneration 
by showing superior collagen II IHC staining of the treated groups compared to the 
non-treated groups in rabbit models. Superior collagen II staining was shown in a 
few cell-based approaches. For example, in 2008, Funayama et al.124 showed 
collagen II production when a type II collagen solution mixed with allogeneic 
chondrocytes was injected into patellar groove osteochondral defects (5 mm 
diameter, 4 mm depth) of rabbits (n=2) after 24 weeks. In 2016, Kuo et al.125 
implanted chitosan/chondroitin-6-sulfate/hyaluronan (GCH) cryogel scaffolds 
seeded with allogeneic chondrocytes in patellar groove defects (4 mm in diameter 
and 2 mm in thickness) of rabbits (n=4), and after 12 weeks the collagen II IHC of 
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the defects supported collagen II production. In 2017,  Park et al.126 implanted a 
composite of HA and human umbilical cord blood-derived mesenchymal stem cells 
into the patellar groove defects (3 mm in diameter and 3 mm in depth) of rabbits 
(n=10), and after 16 weeks collagen II production was shown in the defects. In 
addition to the cell-based approaches the incorporation of growth factors in the 
scaffolds have shown collagen II production in the regenerated tissue of rabbit 
models; in 2017, Betz et al.127 press-fitted autologous muscle tissue fragments 
(treated with BMP-2) in the medial femoral condyle defects (diameter 4 mm, depth 
5 mm) of rabbits (n=7). After 8 weeks collagen II production confirmed with IHC 
was observed in the in the defects. In 2016, implanting alginate gels containing 
stromal cell-derived factor (SDF)-1 in patellar groove defects (4.5 mm in diameter 
and 3 mm in depth) of rabbits (n=5) led to superior collagen II production 
(confirmed by IHC) after 16 weeks compared to the untreated defects.  
 
Incorporation of cells in cartilage regeneration approaches has therefore 
shown promising results and might be necessary for treatments of large cartilage 
defects; however, the translational limitations of cell-based therapies such as high 
cost, the need for two separate surgeries, and regulatory challenges have inspired 
the biomaterials community to develop alternative strategies. Employing 
chondroinductive growth factors in cartilage regeneration approaches might be 
advantageous to overcome the cell-based therapy limitations and the clinical 
approval of the number of growth factor based products demonstrate a significant 
step for overcoming their regulatory barriers.117 However, the drawbacks 
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associated with growth factors—in addition to their high cost and the associated 
regulatory classification as a combination product—is their potential for eliciting 
ectopic tissue formation in vivo. In addition, their short half-life suggests that they 
need a carrier system to enhance their tissue regeneration potential. The bottom 
line is that growth factor inclusion, with all translational risks aside, still requires the 
design of a delivery system that ensures targeted and on demand delivery of the 
therapeutic is necessary. 
 
The current study was the first in vivo analysis of the SPPEPS peptide, 
conducted with a fast-crosslinking PHA hydrogel as the biomaterial platform. With 
this proof of concept in place, the results of the current study provide the motivation 
and rationale for follow up studies with larger animal numbers to allow for additional 
tastings. In the current study, only one concentration of the SPPEPS peptide was 
analyzed. It would be valuable to explore not only different concentrations of the 
SPPEPS sequence, but further to evaluate the chondroinductivity of the peptide in 
combination with adhesion peptides such as RGD or other potential 
chondroinductive sequences such as Link N or B2A. Furthermore, different 
biomaterial carrier systems may be explored to support osteochondral 
regeneration. In addition, larger animal numbers will allow for functional 
mechanical testing that would have been premature to include in the current study.  
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Conclusion 
The current study investigated the chondroinductivity of a novel bioactive 
peptide (SPPEPS) conjugated to a PHA hydrogel. Although the gross morphology 
did not identify significant differences among the groups, the collagen II 
immunostaining demonstrated the potential of the SPPEPS peptide in enhancing 
chondrogenic differentiation of the infiltrated BMSCs and production of a hyaline-
like cartilage tissue. Identifying bioactive peptides and incorporating them in 
cartilage regeneration strategies may lead to the design of chondroinductive 
materials without the need for adding cells of any kind or growth factors, which 
would be tremendously beneficial from a translational perspective.  
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Chapter 5: Conclusion 
The current dissertation has successfully introduced the capabilities of a 
novel synthetic peptide, SPPEPS, in inducing chondrogenesis in vitro and in vivo. 
In regenerative medicine, developing strategies that do not rely on cell sources or 
natural stimuli to produce the targeted tissue, are advantageous for translational 
purposes. The cell-based therapies have limitations for the patients such as high 
cost, long recovery time and need for two separate surgeries (harvesting and 
implanting the cells). In addition, the need for GMP facilities and the surgeons’ 
training add more obstacles for developing across-the-board strategies. 
Incorporation of animal-derived components such as growth factors have 
regulatory complications (i.e., combination product) in addition to their high cost. 
The lack of specificity in natural components may lead to ectopic tissue formation 
or tumorigenesis. One classic example of ectopic tissue formation happened with 
bone morphogenetic protein-2 (BMP-2). The application of BMP-2 for posterior 
lumbar interbody fusion (PLIF) was halted by the Federal Food and Drug 
Administration (FDA) when their trial study indicated that the application of BMP-2 
elevated the incidence of ectopic bone formation in the neural canal.128 Small 
peptides reduce the chance of nonspecific binding, which means that they may be 
incorporated in biomaterials to elicit a desired and targeted cell response. 
Furthermore, peptides are easy to synthesize in large quantities with lower price 
compared to natural molecules and can easily be immobilized to the carrier 
biomaterial to avoid challenges with controlled release. 
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The cell-binding ability of synthetic peptides was first shown in 1984,75 when 
fibronectin cell-binding was duplicated with a three amino acid peptide, Arg-Gly-
Asp (RGD), which is found in the cell attachment domain of fibronectin. Later on, 
it was shown that RGD is the cell attachment site of many other adhesion 
proteins.76-79, 129 RGD is a good example that demonstrates a specific binding 
sequence can be reduced to a short peptide, and the peptide can be used instead 
of growth factors, antibodies, and ECM proteins.82-85, 129 To successfully draw out 
a desired response from synthetic peptides, understanding the cellular signaling 
networks is crucial. The mechanisms of many cellular interactions are not fully 
understood; however, the advance of high-throughput measurements and genome 
sequencing enable us to collect comprehensive data sets, which can eventually 
lead us to theory formation and computational prediction of the cellular signaling 
networks.130  
 
In this thesis, my goal was to find a peptide that specifically affects 
chondrogenic differentiation, which led us to the matching sequence of 
chondroinductive molecules and for further analysis the peptide was crosslinked 
to pentenoate-functionalized hyaluronic acid (PHA) hydrogels.  
 
The physical properties of hydrogels have made them attractive for many 
different applications in regenerative medicine. Properties such as capabilities of 
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filling any shape of defect, the crosslinking after placing the material, which keeps 
the material in place and the fact that other molecules can be encapsulated in a 
hydrogel network. Hyaluronic acid (HA) hydrogels specifically have been a focus 
area of interest in regenerative medicine because HA has a crucial role in different 
cellular and tissue functions66, 131-134 and HA hydrogels mimic salient elements of 
native extracellular matrices (ECMs) and can support cell adhesion.133 
The current dissertation successfully demonstrated the potential of the 
SPPEPS peptide in inducing chondroinductivity when the peptide significantly 
enhanced the expression of chondrogenic markers; however, the proteomics 
analysis indicated that the peptide alone was not sufficient for mimicking 
transforming growth factor-beta 3 (TGF-3). Identifying more chondroinductive 
sequences and studying their synergistic effects might be a promising route for 
designing biomaterials with the potential of expressing a protein profile similar to 
the one stimulated by TGF-3.  
 
The in vitro evaluations do not always translate successfully to in vivo 
models, the changes in cellular environment and mechanical forces are 
oversimplified in in vitro models. The costs related to use of animal models does 
not make the in vivo analysis always possible. For the future analysis, 
improvement of the in vitro models such as 3D cell culture or simulating 
mechanical forces in vitro might help to develop better in vitro models. 
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Despite the TCT plates study, the in vitro analysis of the hydrogels indicated 
no significant difference of chondrogenic marker expression between the groups 
with or without the SPPEPS conjugation. However, the hydrogels with both RGD 
and SPPEPS peptides conjugated to PHA showed superiority in terms of 
supporting chondrogenic differentiation, which further indicated the role of cellular 
adhesion in supporting chondrogenic differentiation. In the hydrogel study only one 
concentration of the peptide was tested; therefore, analyzing PHA hydrogels with 
various concentrations of the peptide may be advised in the future.  
 
For the in vivo study, the scoring of the gross morphology did not indicate 
any significant differences among the groups, although the collagen II 
immunohistochemistry indicated the potential of the SPPEPS peptide in inducing 
chondrogenic differentiation in the defects; however, the results were not 
consistent in all the samples, which may suggest that larger sample numbers might 
be needed. In addition, the mechanical properties of the regenerated tissue were 
not evaluated, which can be considered for future analysis. The mechanical 
properties of hydrogels do not necessarily mimic the cartilage ECM. This limitation 
might be addressed by designing multi-material constructs where one material 
supports the mechanical integrity and the other mimics the biological properties of 
cartilage ECM. The material can further be custom-made, and 3D printed for 
irregular shapes.  
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The current dissertation has successfully created a new route for designing 
chondroinductive biomaterials. Replacing natural molecules with synthetic 
peptides may lead to designing of biomaterials tailored to receptor–peptide 
interactions, which will be the next generation of biomaterials for cartilage 
regeneration; however, this would not be possible without fully understanding of 
the mechanism of chondrogenic differentiation, which might be achieved by high 
through-put analysis of cellular networks.  
 
This dissertation has successfully identified a chondroinductive peptide 
sequence (SPPEPS) and demonstrated its potential in inducing chondroinductivity 
in 2D cell culture for in vitro study when the peptide was conjugated to hydrogels 
for in vitro and in vivo study,  
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Figure 2.1: Chondrocyte Integrin Expression 
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Figure 3.1. DNA Content Analysis of the rBMSCs on Hydrogel Surface after 
3 Days.  
Individual conjugation of SPPEPS and RGD to PHA decreased the cell content; 
however, the cell contents are less than the PHA group when RGD and SPPEPS 
peptides are incorporated in the hydrogels individually, however; the cell content 
is comparable with PHA group, when both SPPEPS and RGD peptides are 
incorporated in the hydrogels. PHA = 5% (w/v) pentanoate-functionalized 
hyaluronic acid with no peptide conjugation, PHA+RGD = PHA conjugated to 1.5 
mM GCGYGRGDSPG, PHA+SP = PHA conjugated to 1.5 mM GCGYGSPPEPS, 
PHA+PS = PHA conjugated to 1.5 mM GCGYGPSEPSP (scrambled SPPEPS), 
PHA+RGD+SP = PHA conjugated to 1.5 mM GCGYGRGDSPG and 1.5 mM 
GCGYGSPPEPS. (* and #) = p < 0.05 compared to the TCT plate group and the 
PHA group, respectively. Data are reported as mean + standard deviation (n=3). 
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Figure 3.2. Gene Expression Analyses of rBMSCs on TCT Plates Measured 
by rt-PCR after 3 Days. 
 For the SPPEPS 100 ng/mL group, the collagen type II and aggrecan gene 
expressions were 1.5 times and 35% higher than the control group, respectively. 
(*, #, % and &) = p < 0.05 compared to the Control, SPPEPS 50, 100 and 500 ng/mL 
respectively. (**) = p < 0.001 compared to the Control. Data are reported as mean 
+ standard deviation (n=6). 
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Figure 3.3. Gene Expression Analysis of rBMSCs on Hydrogel Surfaces 
Measured by rt-PCR after 3 Days.  
Combined effects of SPPEPS and RGD conjugation induced collagen type II gene 
expression far superior to either peptide individually. PHA = 5% (w/v) pentanoate-
functionalized hyaluronic acid with no peptide conjugation, PHA+RGD = PHA 
conjugated to 1.5 mM GCGYGRGDSPG, PHA+SP = PHA conjugated to 1.5 mM 
GCGYGSPPEPS, PHA+PS = PHA conjugated to 1.5 mM GCGYGPSEPSP 
(scrambled SPPEPS), PHA+RGD+SP = PHA conjugated to 1.5 mM 
GCGYGRGDSPG and 1.5 mM GCGYGSPPEPS. (* and #) = p < 0.05 compared 
to the TCT plate group and PHA+SP+RGD respectively. Data are reported as 
mean + standard deviation (n=4).   
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Figure 3.4. Proteomics Analysis, Volcano Plots for 7 and 14 Days. 
440, 429, 372 and 275 proteins were expressed in positive control day 7, SPPEPS 
day 7, positive control day 14, and SPPEPS day 14, respectively (each with a 
significant change compared to the negative control). Positive control=TGF-3 (10 
ng/mL). SPPEPS=SPPEPS 100 ng/mL. –Log 10 (P-value) > 1.3 is considered to 
be significant (i.e., Log 10 (0.05) =1.301), (n=4). 
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Figure 3.5. Proteomics Analysis. Common Proteins Expressed in SPPEPS 
and Positive Control Groups at 14 Days.  
26 common proteins were expressed in SPPEPS and Positive Control Groups at 
14 days, with a significant increase compared to the Negative Control. The blue 
circles represent CLIC4 and ENPP1 genes that play important roles in 
chondrogenic differentiation. SPPEPS = SPPEPS 100 ng/mL, positive control = 
TGF-3 (10 ng/mL). –Log 10 (P-value) > 1.3 is considered significant (n=4). 
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Figure 3.6. Proteomics Analysis, collagen type XIα1 Expression.  
Collagen XIα1 content significantly increased in both the positive and SPPEPS 
groups when the data were normalized to the negative control. SPPEPS = 
SPPEPS 100 ng/mL, positive control = TGF-3 (10 ng/mL). –Log 10 (P-value) > 
1.3 is considered significant (n=4). 
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Figure 3.7. Proteomics Analysis, Kyoto Encyclopedia of Genes and 
Genomes (KEGG) Pathways.  
At 14 days, in both SPPEPS 100 ng/mL and TGF-3 (10 ng/mL) groups, KEGG 
pathway analysis of the proteins that were significantly higher from negative control 
indicate that the “Insulin Signaling Pathway” was activated through the GSK3- 
gene, which is known to be an essential gene for early stage chondrocyte 
differentiation. 
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Figure 3.8. Preliminary Study, Gene Expression Analyses of rBMSCs on 
TCT Plates Measured by rt-PCR after 3 Days. 
Collagen type II gene expression for SPPEPS (100 ng/mL) was 3.3 times higher 
compare to the control group. Control = rBMSCs on TCT plates with no peptide or 
growth factors in the cell culture medium. TGF-3 = transforming growth factor-3 
dissolved in cell culture medium. Link N = Link N (ASP-HIS-LEU-SER-ASP-ASN-
TYR-THR-LEU-ASP-HIS-ASP-ARG-ALA-ILE-HIS, DHLSDNYTLDHDRAIH) 
peptide sequence, SPPEPS = Ser-Pro-Pro-Glu-Pro-Ser peptide sequence, 
matching sequence of aggrecan proteoglycan and TGF-3. (*) = p < 0.05 compared 
to the control. Data are reported as mean + standard deviation (n=3). 
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Figure 3.9. H 1NMR analysis  
(A) 60 kDa PHA, and (B) 60 kDa PHA with conjugated GCGYGRGDSPG. (Varian 
Mercury VNMRS 400 MHz spectrometer).  
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Figure 4.1: Surgical Procedure (Sequence of Steps) 
 (1) Pilot hole (1 mm diameter) was created in the femoral condylar cartilage. (2) The hole 
was enlarged to 3.5 mm diameter. (3) Microdrilling of 4 holes (0.4 mm in diameter) in the 
subchondral bone stimulated bone marrow to the defect area. (4 and 5) The hydrogel 
precursor was implanted in the defect with needle and syringe. (6) The hydrogel was 
photocrosslinked for 5 minutes. 
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Figure 4.2: Representative Gross Morphological Images 
The images represent the worst, intermediate and best gross morphology of rabbit 
condyle defects 12 weeks post-surgery. For all the groups, we observed variability 
in the regenerated tissues; however, the best PHA+RGD sample regenerated the 
tissue most similar in appearance to the healthy cartilage. Control = The defect 
with no implanted material, PHA = 5% pentanoate-functionalized hyaluronic acid 
+ 5% hyaluronic acid nanoparticles, PHA+RGD = PHA conjugated to 2 mM RGD, 
PHA+SP = PHA conjugated to 2 mM SPPEPS. The text under each image 
represent rabbit number and knee side. (e.g., 1R = Rabbit #1, right knee). Each 
interval on the rulers indicates 1 mm. 
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Figure 4.3: Gross Morphology Scoring 
Average morphological score (max score = 10), and mean percentage of repaired 
tissue in rabbit condyle defects 12 weeks post-surgery (n=6). Only two condyles 
scored 10 for average morphological and had 100% regenerated tissue and both 
the were from the PHA+RGD group. No significant differences were observed 
among the groups. Control = The defect with no implanted material, PHA = 5% 
pentanoate-functionalized hyaluronic acid + 5% hyaluronic acid nanoparticles, 
PHA+RGD = PHA conjugated to 2 mM RGD, PHA+SP = PHA conjugated to 2 mM 
SPPEPS.  
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Figure 4.4: Histology Score Distribution 
Stacked column plot compared each of the histological scores and the average 
histology score for each group, values represent mean + standard deviation (n=6). 
The histology scoring system is explained in Table 3.  There was a more frequent 
presence of the high score (e.g., 3) for the PHA+SP and Control groups, and there 
were no examples of “0” score for either of the peptide groups. Control = The defect 
with no implanted material, PHA = 5% pentanoate-functionalized hyaluronic acid 
+ 5% hyaluronic acid nanoparticles, PHA+RGD = PHA conjugated to 1.5 mM RGD, 
PHA+SP = PHA conjugated to 1.5 mM SPPEPS.  
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Figure 4.5. H&E Staining  
Histological analysis of rabbit condyle defects at 12 weeks post-surgery (n=6). 
Sections were taken in the frontal plane and were stained with hematoxylin and 
eosin (H&E). The microscopic observations indicated the structural variability of 
the regenerated tissue within all the groups; however, we observed that 
incorporation of the peptides (PHA+SP and PHA+RGD groups) elevated the 
structural integrity compared to the PHA group. Control = The defect with no 
implanted material, PHA = 5% pentanoate-functionalized hyaluronic acid + 5% 
hyaluronic acid nanoparticles, PHA+RGD = PHA conjugated to 1.5 mM RGD, 
PHA+SP = PHA conjugated to 1.5 mM SPPEPS. The text under each staining 
represent rabbit number and knee side. (e.g., 1R = Rabbit #1, right knee) The 
arrows are pointed at the edges of the defects. Scale bars = 1 mm. 
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Figure 4.6. Alcian Blue Staining  
Histological analysis of rabbit condyle defects at 12 weeks post-surgery (n=6). 
Sections were taken in the frontal plane and were stained with Alcian Blue. The 
stain intensities were superior in the control and PHA+SP group compared to the 
other groups. Control = The defect with no implanted material, PHA = 5% 
pentanoate-functionalized hyaluronic acid + 5% hyaluronic acid nanoparticles, 
PHA+RGD = PHA conjugated to 1.5 mM RGD, PHA+SP = PHA conjugated to 1.5 
mM SPPEPS. The text under each staining represent rabbit number and knee 
side. (e.g., 1R = Rabbit #1, right knee). Arrows indicate the edges of the defects. 
Scale bars = 1 mm. 
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Figure 4.7. Collagen II Immunohistochemistry  
Histological analysis of rabbit condyle defects at 12 weeks post-surgery (n=6). 
Sections were taken in the frontal plane and were stained with collagen type II 
antibody. 3R, 7R and 9L condyles from PHA+SP group and 2R condyles from 
Control showed the most intense and prevalent collagen II staining, which 
indicated the superior potential of the PHA+SP group in collagen type II production. 
Control = The defect with no implanted material, PHA = 5% pentanoate-
functionalized hyaluronic acid + 5% hyaluronic acid nanoparticles, PHA+RGD = 
PHA conjugated to 1.5 mM RGD, PHA+SP = PHA conjugated to 1.5 mM SPPEPS. 
The text under each staining represent rabbit number and knee side. (e.g., 1R = 
Rabbit #1, right knee). The arrows are pointed at the edges of the defects. Scale 
bars = 1 mm. 
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Figure 4.8: Representative Magnified Collagen II IHC 
Histological analysis of rabbit condyle defects after 12 weeks post-surgery (n=6). 
Sections were taken in the frontal plane and were stained with collagen type II 
antibody. Magnified images shown below each overall section correlate to the box 
above. The magnified image of 3L condyle revealed the unstained cellular clusters. 
Magnified microscopic images of 3R and 7R condyles showed the chondrocyte 
formation in the cartilage zones, with staining being more intense around regions 
of chondrocyte-like cells in some areas. Control = The defect with no implanted 
material, PHA = 5% pentanoate-functionalized hyaluronic acid + 5% hyaluronic 
acid nanoparticles, PHA+RGD = PHA conjugated to 1.5 mM RGD, PHA+SP = PHA 
conjugated to 1.5 mM SPPEPS. The text under each staining represent rabbit 
number and knee side. (e.g., 1R = Rabbit one, right knee) The arrows are pointed 
at the edges of the defects. Scale bars = 1 mm. 
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Figure 4.9. H 1NMR Analysis of 60 kDa PHA  
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Appendix B: Tables  
Chapter 1: No Tables  
Chapter 2: Table 2.1 
Chapter 3: Table 3.1 
Chapter 4: Table 4.1-4.3 
Chapter 5: No Tables 
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Table 2.1 Integrin-Binding Peptides identified for cancer therapy 
applications 
 
Discovery 
Method 
Receptor Sequence Application 
OBOC 
α4β1 LTGpLDI135 Leukemia 
α3β1 cdGLGBNc136 (LXYI) 
Breast 
cancer 
Panning 
in vitro 
αvβ3 CQQSNRGDRKRC137(RMS-I) 
Rhabdo-
myosarcoma 
cancer 
αvβ6 RGDLATLRQLAQEDGVVGVR138 Lung cancer 
α4β1 CPLDIDFYC139 (pIII) Leukemia 
Panning 
in vivo 
α3β1 SWKLPPS140 
Gastric 
Cancer 
αvβ3 CRGDKGPDC141 
Prostate 
Cancer 
Phage 
display 
library 
αvβ6 RTDLDSLRTYTL142 
Ovarian 
cancer 
αvβ3 CDCRGDCFC 143, 144 
Breast 
Cancer 
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Table 3.1: List of Synthesized Peptides 
 
Peptide Sequence MW Description 
1 GRGDSP  587.59 Adhesion peptide 
2 GCGYGRGDSPG  1025.06 RGD with spacer 
3 SPPEPS 612.63 Chondroinductive peptide 
4 GCGYGSPPEPS  1050.10 SPPEPS with spacer 
5 GCGYGPSEPSP  1050.10 Scrambled SPPEPS with 
spacer 
6 DHLSDNYTLDHDRAIH   1921.99 Link N sequence 
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Table 4.1 List of Group Placement and Outcome Analysis for Each Rabbit 
Knee  
 
Animal no Left Knee Right Knee 
Time 
(Weeks) 
Analysis 
Rabbit 1 Control PHA 12 
Morphology 
and histology 
Rabbit 2 PHA+RGD Control 12 
Morphology 
and histology 
Rabbit 3 Control PHA+SP 12 
Morphology 
and histology 
Rabbit 4 PHA PHA+SP 12 
Morphology 
and histology 
Rabbit 5 PHA+RGD PHA 12 
Morphology 
and histology 
Rabbit 6 PHA+SP PHA+RGD 12 
Morphology 
and histology 
Rabbit 7 PHA PHA+SP 12 
Morphology 
and histology 
Rabbit 8 PHA+RGD PHA 12 
Morphology 
and histology 
Rabbit 9 PHA+SP PHA+RGD 12 
Morphology 
and histology 
Rabbit 10 Control PHA 12 
Morphology 
and histology 
Rabbit 11 PHA+RGD 
 
Control 
12 
Morphology 
and histology 
Rabbit 12 Control PHA+SP 12 
Morphology 
and histology 
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Table 4.2: Scoring Table for Morphological Analysis 
 
Feature Score 
Repair tissue or test article present in implant site  
Full presence 2 
Partial 1 
None 0 
Edge integration (New tissue relative to native 
cartilage) 
 
Full 2 
Partial 1 
None 0 
Smoothness of repair surface  
Smooth 2 
Intermediate 1 
Rough/Missing 0 
Cartilage surface degree of filling  
Flush 2 
Slight depression 1 
Depressed/Overgrown 0 
Color of cartilage (opacity/translucency of repair 
tissue) 
 
Translucent 2 
Opaque 1 
Missing 1 
Amount of repair tissue relative to total area of defect 
(estimated) 
% present 
in defect. 
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Table 4.3: Histology Grading System 
 
Feature Feature 
Cellular morphology 
 
Hyaline cartilage  4 
Mostly hyaline cartilage   3 
Mixed hyaline and fibrocartilage   2 
Mostly fibrocartilage   1 
Some fibrocartilage and mostly nonchondrocytic cells  0 
Staining   
Normal to nearly normal 3 
Moderate 2 
Slight 1 
None 0 
Cartilage thickness   
Similar to the surrounding cartilage   3 
Greater than the surrounding cartilage  2 
Less than the surrounding cartilage  1 
No cartilage   0 
Reconstruction of subchondral bone 
Normal 3 
Reduced subchondral bone reconstruction 2 
Minimal subchondral bone reconstruction 1 
No subchondral bone reconstruction 0 
Edge integration   
Bonded at both ends of graft  2 
Bonded at 1 end or partially at both ends  1 
Not bonded  0 
 
 
